ALNY
Alnylam Pharmaceuticals Inc.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 02-07-2019 after market close | 11-07-2018 | 08-02-2018 | 05-03-2018 after market close | 02-08-2018 | 11-07-2017 after market close | 08-09-2017 after market close | 05-05-2017 | |
|---|---|---|---|---|---|---|---|---|
| Actual EPS | -2.09 | -2.43 | -1.83 | -1.41 | -1.48 | -1.34 | -1.34 | -1.25 |
| Consensus EPS | -2.27 | -2.02 | -1.74 | -1.48 | -1.38 | -1.23 | -1.45 | -1.22 |
| Estimated EPS | -2.27 | -2.02 | -1.74 | -1.48 | -1.38 | -1.23 | -1.45 | -1.22 |
| Number of Estimates | 5 | 5 | 4 | 6 | 8 | 9 | 8 | 6 |
| EPS Surprise | $0.18 | -$0.41 | -$0.09 | $0.07 | -$0.10 | -$0.11 | $0.11 | -$0.03 |
Stats
Summary
Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.
Market Cap: 13.3 Billion
Primary Exchange: Nasdaq Global Select
Website: http://www.alnylam.com
Shares Outstanding: 99.2 Million
Float: 98.7 Million
Dividend: 0.0 (0.0%)
Beta: 2.669606
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 5.88 Million
Ethical Flags
Longest drawdown: 603 trading days
From: 2015-06-22 To: 2017-11-09
Lowest Point:
Alnylam to Report New Clinical Results for ONPATTRO® (patisiran) at Peripheral Nerve Society (PNS) Annual Meeting and the 5th Congress of the European Academy of Neurology (EAN)
via: Business Wire at 2019-06-13 04:00:00:000
Data from Ongoing Open-Label Extension Study Highlight Durable Halting or Reversal of Neuropathy Disease Progression Relative to Baseline and Consistent Safety Profile of ONPATTRO in Patients with hATTR Amyloidosis Alnylam to Share Data Evaluating Treatment w… read more...
BIIB Is For Buy-O-Gen
via: SeekingAlpha at 2019-06-12 06:30:36:000
Let's spell Biogen Buy-o-Gen. Indeed, BIIB seems increasingly appealing at current price. The biotech focuses on discovering, developing, and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets various products for multiple sc… read more...
Alnylam Pharmaceuticals (ALNY) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-06-10 07:37:51:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Alnylam Pharmaceuticals (ALNY) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-06-10 07:37:51:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Alnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria
via: Business Wire at 2019-06-05 03:00:00:000
First Potential Treatment Demonstrating Substantial Reduction in the Frequency of Porphyria Attacks Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Applicati… read more...
Alnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria
via: Business Wire at 2019-06-05 03:00:00:000
First Potential Treatment Demonstrating Substantial Reduction in the Frequency of Porphyria Attacks Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Applicati… read more...
Alnylam Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration (FDA) for Givosiran for the Treatment of Acute Hepatic Porphyria
via: Business Wire at 2019-06-05 03:00:00:000
First Potential Treatment Demonstrating Substantial Reduction in the Frequency of Porphyria Attacks Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the completion of the rolling submission of a New Drug Applicati… read more...
Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
via: Business Wire at 2019-05-31 03:00:00:000
Initial Results Expected in Late 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the first patient has been dosed in the Companys Phase 1 study of ALN-AGT, an investigational RNAi therapeut… read more...
Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
via: Business Wire at 2019-05-31 03:00:00:000
Initial Results Expected in Late 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the first patient has been dosed in the Companys Phase 1 study of ALN-AGT, an investigational RNAi therapeut… read more...
Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
via: Business Wire at 2019-05-31 03:00:00:000
Initial Results Expected in Late 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the first patient has been dosed in the Companys Phase 1 study of ALN-AGT, an investigational RNAi therapeut… read more...
Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
via: Business Wire at 2019-05-31 03:00:00:000
Initial Results Expected in Late 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the first patient has been dosed in the Companys Phase 1 study of ALN-AGT, an investigational RNAi therapeut… read more...
Alnylam Doses First Patient in Phase 1 Study of ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension
via: Business Wire at 2019-05-31 03:00:00:000
Initial Results Expected in Late 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the first patient has been dosed in the Companys Phase 1 study of ALN-AGT, an investigational RNAi therapeut… read more...
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
via: Business Wire at 2019-05-30 12:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Jefferies 2019 Global Healthcare Conference on Friday, June 7, 2019 at 10:30 am ET in New York City Go… read more...
Alnylam Announces New Leadership Appointments
via: Business Wire at 2019-05-29 04:00:00:000
Company Appoints Chief Human Resources Officer and Chief Scientific Officer Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of Kelley Boucher as the Companys Senior Vice President (SV… read more...
Pfizer Nabs Regulatory Approval For Tafamidis, An FDA First Is Achieved
via: SeekingAlpha at 2019-05-20 13:58:00:000
Pfizer ( PFE ) was able to obtain FDA approval for its drugs by the name of Vyndaqel and Vyndamax (tafamidis) to treat patients with transthyretin amyloid cardiomyopathy. This is a good approval for the company because it has given itself a great opportunity to target a space with no competi… read more...
Pfizer Nabs Regulatory Approval For Tafamidis, An FDA First Is Achieved
via: SeekingAlpha at 2019-05-20 13:58:00:000
Pfizer ( PFE ) was able to obtain FDA approval for its drugs by the name of Vyndaqel and Vyndamax (tafamidis) to treat patients with transthyretin amyloid cardiomyopathy. This is a good approval for the company because it has given itself a great opportunity to target a space with no competi… read more...
Pfizer Nabs Regulatory Approval For Tafamidis, An FDA First Is Achieved
via: SeekingAlpha at 2019-05-20 13:58:00:000
Pfizer ( PFE ) was able to obtain FDA approval for its drugs by the name of Vyndaqel and Vyndamax (tafamidis) to treat patients with transthyretin amyloid cardiomyopathy. This is a good approval for the company because it has given itself a great opportunity to target a space with no competi… read more...
Moderna Aims To Revolutionize Modern Medicine With A New Class Of Drugs
via: SeekingAlpha at 2019-05-16 11:44:44:000
Messenger RNA therapeutics company, moderna ( MRNA ), if successful, could completely transform modern medicine. We're talking a potential paradigm-shift here. They're using messenger RNA (mRNA) to treat a variety of diseases with their three programs covering immuno-oncology, vaccines for u… read more...
Moderna Aims To Revolutionize Modern Medicine With A New Class Of Drugs
via: SeekingAlpha at 2019-05-16 11:44:44:000
Messenger RNA therapeutics company, moderna ( MRNA ), if successful, could completely transform modern medicine. We're talking a potential paradigm-shift here. They're using messenger RNA (mRNA) to treat a variety of diseases with their three programs covering immuno-oncology, vaccines for u… read more...
Moderna Aims To Revolutionize Modern Medicine With A New Class Of Drugs
via: SeekingAlpha at 2019-05-16 11:44:44:000
Messenger RNA therapeutics company, moderna ( MRNA ), if successful, could completely transform modern medicine. We're talking a potential paradigm-shift here. They're using messenger RNA (mRNA) to treat a variety of diseases with their three programs covering immuno-oncology, vaccines for u… read more...
How Regeneron Can Take Its Sad Song And Make It (Much) Better
via: SeekingAlpha at 2019-05-12 22:11:43:000
Introduction - more unforced errors Regeneron ( REGN ) fell more last week first on this sort of headline from Seeking Alpha: Regeneron down 7% on Q1 miss, toxicity questions on candidate REGN1979 . Further embarrassment came later in the day, when the company quickly issued an ame… read more...
How Regeneron Can Take Its Sad Song And Make It (Much) Better
via: SeekingAlpha at 2019-05-12 22:11:43:000
Introduction - more unforced errors Regeneron ( REGN ) fell more last week first on this sort of headline from Seeking Alpha: Regeneron down 7% on Q1 miss, toxicity questions on candidate REGN1979 . Further embarrassment came later in the day, when the company quickly issued an ame… read more...
How Regeneron Can Take Its Sad Song And Make It (Much) Better
via: SeekingAlpha at 2019-05-12 22:11:43:000
Introduction - more unforced errors Regeneron ( REGN ) fell more last week first on this sort of headline from Seeking Alpha: Regeneron down 7% on Q1 miss, toxicity questions on candidate REGN1979 . Further embarrassment came later in the day, when the company quickly issued an ame… read more...
Alnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019
via: Business Wire at 2019-05-09 03:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Merrill Lynch Health Care Conference 2019 on Thursday, May 16, 2019 at 9:20 am PT (12:20 pm ET) at the Encore Hotel in… read more...
Alnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019
via: Business Wire at 2019-05-09 03:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Merrill Lynch Health Care Conference 2019 on Thursday, May 16, 2019 at 9:20 am PT (12:20 pm ET) at the Encore Hotel in… read more...
Alnylam to Webcast Presentation at Bank of America Merrill Lynch Health Care Conference 2019
via: Business Wire at 2019-05-09 03:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Bank of America Merrill Lynch Health Care Conference 2019 on Thursday, May 16, 2019 at 9:20 am PT (12:20 pm ET) at the Encore Hotel in… read more...
Alnylam down 6% on FDA OK of Pfizer's tafamidis
via: SeekingAlpha at 2019-05-06 09:26:42:000
Alnylam Pharmaceuticals ( ALNY -5.5% ) slips on more than double normal volume in apparent reaction to the FDA nod for Pfizer's VYNDAQEL (tafamidis meglumine) and VYNDAMAX (tafamidis) for the treatment of cardiomyopathy associated with hereditary transthyretin-mediated amyloidosis (hATTR… read more...
Alnylam down 6% on FDA OK of Pfizer's tafamidis
via: SeekingAlpha at 2019-05-06 09:26:42:000
Alnylam Pharmaceuticals ( ALNY -5.5% ) slips on more than double normal volume in apparent reaction to the FDA nod for Pfizer's VYNDAQEL (tafamidis meglumine) and VYNDAMAX (tafamidis) for the treatment of cardiomyopathy associated with hereditary transthyretin-mediated amyloidosis (hATTR… read more...
Alnylam down 6% on FDA OK of Pfizer's tafamidis
via: SeekingAlpha at 2019-05-06 09:26:42:000
Alnylam Pharmaceuticals ( ALNY -5.5% ) slips on more than double normal volume in apparent reaction to the FDA nod for Pfizer's VYNDAQEL (tafamidis meglumine) and VYNDAMAX (tafamidis) for the treatment of cardiomyopathy associated with hereditary transthyretin-mediated amyloidosis (hATTR… read more...
Alnylam Posts Another Encouraging Quarter Early In Onpattro's Launch
via: SeekingAlpha at 2019-05-02 06:53:12:000
As difficult as it is to get a drug from the lab to the market, that's only part of the formula for success for biotechs - successful commercialization is every bit as important, and commercialization can have its own frustrating bumps along the road. While I see nothing wrong with the launch … read more...
Alnylam Posts Another Encouraging Quarter Early In Onpattro's Launch
via: SeekingAlpha at 2019-05-02 06:53:12:000
As difficult as it is to get a drug from the lab to the market, that's only part of the formula for success for biotechs - successful commercialization is every bit as important, and commercialization can have its own frustrating bumps along the road. While I see nothing wrong with the launch … read more...
Alnylam Posts Another Encouraging Quarter Early In Onpattro's Launch
via: SeekingAlpha at 2019-05-02 06:53:12:000
As difficult as it is to get a drug from the lab to the market, that's only part of the formula for success for biotechs - successful commercialization is every bit as important, and commercialization can have its own frustrating bumps along the road. While I see nothing wrong with the launch … read more...
Alnylam Onpattro sales $26.3M in Q1
via: SeekingAlpha at 2019-05-01 12:37:49:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) Q1 results ($M): ONPATTRO sales: $26.3M. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q1 2019 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-05-01 10:36:24:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2019 Earnings Conference Call May 01, 2019, 08:30 ET Company Participants Christine Lindenboom - VP, IR & Communications John Maraganore - CEO & Executive Director Akshay Vaishnaw - President, Research & Development Barry Gree… read more...
Alnylam Pharmaceuticals, Inc. 2019 Q1 - Results - Earnings Call Slides
via: SeekingAlpha at 2019-05-01 06:23:41:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2019 Q1 earnings Read more … read more...
Alnylam Q1 ONPATTRO sales $26.3M
via: SeekingAlpha at 2019-05-01 05:55:04:000
Alnylam Pharmaceuticals ( ALNY -5.7% ) Q1 results : Revenues: $33.3M (+52.1%); ONPATTRO: $26.3M; Net revenues from collaborators: $7M. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...
Alnylam Pharmaceuticals beats by $0.38, beats on revenue
via: SeekingAlpha at 2019-05-01 04:06:06:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q1 Non-GAAP EPS of -$1.42 beats by $0.38 ; GAAP EPS of -$1.73. More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Alnylam Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Period Activity
via: Business Wire at 2019-05-01 04:00:00:000
Achieved First Quarter 2019 ONPATTRO Global Net Product Revenues of $26.3 Million with Over 400 Patients on Commercial Product Worldwide Achieved Positive Results in ENVISION Phase 3 Study of Givosiran Formed Broad Collabora… read more...
Alnylam Highlights Progress on Global Market Access for ONPATTRO (patisiran)
via: Business Wire at 2019-04-30 12:00:00:000
In the United States, Company Completes Tenth Value-Based Agreement with Commercial Payers, and Achieves Confirmed Access to ONPATTRO for Greater than 90 Percent of Covered Lives In Europe, Company Achieves Favorable Health Technology Assessment Ratings for O… read more...
Eli Lilly Looks To Tap Potential Groundbreaking Technology From Avidity
via: SeekingAlpha at 2019-04-24 11:47:43:000
Eli Lilly ( LLY ) announced that it had developed a partnership with Avidity Biosciences Incorporated. The reason why is because Eli Lilly wants to tap into Avidity's technology which taps into an interesting mix of antibodies and oligonucleotides. With this platform, it hopes to be able t… read more...
Eli Lilly Looks To Tap Potential Groundbreaking Technology From Avidity
via: SeekingAlpha at 2019-04-24 11:47:43:000
Eli Lilly ( LLY ) announced that it had developed a partnership with Avidity Biosciences Incorporated. The reason why is because Eli Lilly wants to tap into Avidity's technology which taps into an interesting mix of antibodies and oligonucleotides. With this platform, it hopes to be able t… read more...
Eli Lilly Looks To Tap Potential Groundbreaking Technology From Avidity
via: SeekingAlpha at 2019-04-24 11:47:43:000
Eli Lilly ( LLY ) announced that it had developed a partnership with Avidity Biosciences Incorporated. The reason why is because Eli Lilly wants to tap into Avidity's technology which taps into an interesting mix of antibodies and oligonucleotides. With this platform, it hopes to be able t… read more...
Alnylam to Webcast Conference Call Discussing First Quarter 2019 Financial Results
via: Business Wire at 2019-04-23 12:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2019 on Wednesday, May 1, 2019, before the U.S. financial markets open. Management will provide an upda… read more...
Ionis's Spinraza Still Bests Novartis's Zolgensma
via: SeekingAlpha at 2019-04-22 06:40:03:000
Novartis's 8.7 billion bet Last year Novartis ( NVS ) made waves by acquiring the gene therapy company AveXis for an astounding 8.7 billion dollars , setting in motion a rush of additional buyouts in this therapeutic space including Spark Therapeutics (4.8 billion) and Nightstar Therapeu… read more...
Alnlyam's Positive Phase 3 Results For Givosiran Pushes It Forward For Regulatory Filings
via: SeekingAlpha at 2019-04-18 08:02:24:000
Alnylam ( ALNY ) achieved positive results from its Phase 3 study , using Givosiran to treat patients with acute hepatic porphyria ((AHP)). These results are highly important to Alnylam, because they may likely be able to obtain approval for the drug by sometime next year. There were so… read more...
Alnlyam's Positive Phase 3 Results For Givosiran Pushes It Forward For Regulatory Filings
via: SeekingAlpha at 2019-04-18 08:02:24:000
Alnylam ( ALNY ) achieved positive results from its Phase 3 study , using Givosiran to treat patients with acute hepatic porphyria ((AHP)). These results are highly important to Alnylam, because they may likely be able to obtain approval for the drug by sometime next year. There were so… read more...
Alnlyam's Positive Phase 3 Results For Givosiran Pushes It Forward For Regulatory Filings
via: SeekingAlpha at 2019-04-18 08:02:24:000
Alnylam ( ALNY ) achieved positive results from its Phase 3 study , using Givosiran to treat patients with acute hepatic porphyria ((AHP)). These results are highly important to Alnylam, because they may likely be able to obtain approval for the drug by sometime next year. There were so… read more...
Alnlyam's Positive Phase 3 Results For Givosiran Pushes It Forward For Regulatory Filings
via: SeekingAlpha at 2019-04-18 08:02:24:000
Alnylam ( ALNY ) achieved positive results from its Phase 3 study , using Givosiran to treat patients with acute hepatic porphyria ((AHP)). These results are highly important to Alnylam, because they may likely be able to obtain approval for the drug by sometime next year. There were so… read more...
Alnylam's Partnership With Regeneron Is More Than Meets The Eye
via: SeekingAlpha at 2019-04-16 18:51:07:000
Alnylam ( ALNY ) was able to land a broad partnership deal with Regeneron Pharmaceuticals ( REGN ). This deal was established to partner on developing many products for the eye and central nervous system ((CNS)) disorder indications. There are even additional collaborations expected fo… read more...
Data On Givosiran And Lumasiran Should Help The Alnylam Story
via: SeekingAlpha at 2019-04-16 12:23:46:000
Even as Alnylam ( ALNY ) works toward its second commercial drug filing, questions remain about the safety and efficacy of givosiran, not to mention the platform as a whole. But with good full Phase III data on givosiran and encouraging open-label extension data on lumasiran over the last fe… read more...
Alnylam launches late-stage study of lumasiran in PH1
via: SeekingAlpha at 2019-04-15 05:59:05:000
Alnylam Pharmaceuticals ( ALNY -0.2% ) initiates an open-label Phase 3 clinical trial, ILLUMINATE-B , evaluating lumasiran in infants and young children with primary hyperoxaluria type 1 (PH1), a rare inherited disorder characterized by kidney and bladder stones caused by the buildup … read more...
Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
via: Business Wire at 2019-04-15 03:00:00:000
All Patients in Phase 1/2 Study Have Now Transitioned into Phase 2 OLE Lumasiran Treatment Resulted in 72 Percent Mean Maximal Reduction in Urinary Oxalate Relative to Phase 1/2 Baseline Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the l… read more...
Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
via: Business Wire at 2019-04-12 14:01:00:000
Givosiran Achieved a 74 Percent Mean Reduction in Composite Annualized Attack Rate (AAR) Relative to Placebo, with Consistent Reductions Across all Components of Composite Endpoint and Subgroups Treatment Effect Includes a 90 Percent Median Decrease in Compos… read more...
Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
via: Business Wire at 2019-04-12 14:01:00:000
Givosiran Achieved a 74 Percent Mean Reduction in Composite Annualized Attack Rate (AAR) Relative to Placebo, with Consistent Reductions Across all Components of Composite Endpoint and Subgroups Treatment Effect Includes a 90 Percent Median Decrease in Compos… read more...
Alnylam Presents Positive Complete Results from ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
via: Business Wire at 2019-04-12 14:01:00:000
Givosiran Achieved a 74 Percent Mean Reduction in Composite Annualized Attack Rate (AAR) Relative to Placebo, with Consistent Reductions Across all Components of Composite Endpoint and Subgroups Treatment Effect Includes a 90 Percent Median Decrease in Compos… read more...
"Alnylam Pharmaceuticals (ALNY) To Discuss Regeneron Collaboration - Slideshow "
via: SeekingAlpha at 2019-04-12 10:53:54:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
"Alnylam Pharmaceuticals (ALNY) To Discuss Regeneron Collaboration - Slideshow "
via: SeekingAlpha at 2019-04-12 10:53:54:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
"Alnylam Pharmaceuticals (ALNY) To Discuss Regeneron Collaboration - Slideshow "
via: SeekingAlpha at 2019-04-12 10:53:54:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
NASH players in the red as EASL announcements fail to excite investors
via: SeekingAlpha at 2019-04-11 08:58:25:000
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P… read more...
Alnylam Finds A New Partner For Its Next Phase
via: SeekingAlpha at 2019-04-09 07:05:01:000
Alnylam ( ALNY ) was a very different company five years ago Onpattro was is in Phase II development, fitusiran was in Phase I, and there were still substantial doubts about the entire RNAi concept, as large pharma companies like Novartis ( NVS ) and Merck ( MRK ) were backpedal… read more...
Alnylam Finds A New Partner For Its Next Phase
via: SeekingAlpha at 2019-04-09 07:05:01:000
Alnylam ( ALNY ) was a very different company five years ago Onpattro was is in Phase II development, fitusiran was in Phase I, and there were still substantial doubts about the entire RNAi concept, as large pharma companies like Novartis ( NVS ) and Merck ( MRK ) were backpedal… read more...
Sanofi and Alnylam wrap up research and option phase of collaboration
via: SeekingAlpha at 2019-04-09 03:01:23:000
Sanofi (NASDAQ: SNY ) announces that it and alliance partner Alnylam Pharmaceuticals (NASDAQ: ALNY ) have agreed to conclude the research and option phase of their 2014 RNAi therapeutics collaboration in rare genetic diseases. More news on: Sanofi, Alnylam Pharmaceuticals, Inc., Healthca… read more...
Sanofi and Alnylam wrap up research and option phase of collaboration
via: SeekingAlpha at 2019-04-09 03:01:23:000
Sanofi (NASDAQ: SNY ) announces that it and alliance partner Alnylam Pharmaceuticals (NASDAQ: ALNY ) have agreed to conclude the research and option phase of their 2014 RNAi therapeutics collaboration in rare genetic diseases. More news on: Sanofi, Alnylam Pharmaceuticals, Inc., Healthca… read more...
Regeneron teams up with Alnylam to develop new RNAi therapies
via: SeekingAlpha at 2019-04-08 03:28:21:000
Regeneron Pharmaceuticals (NASDAQ: REGN ) will collaborate with Alnylam Pharmaceuticals (NASDAQ: ALNY ) to discover, develop and commercialize new RNA interference (RNAi) therapeutics for disorders in the eye and central nervous system (CNS) and a select number of target in the liver. Mo… read more...
Sanofi concludes RNAI therapeutics alliance with Alnylam
via: SeekingAlpha at 2019-04-08 03:25:19:000
Sanofi (NASDAQ: SNY ) and Alnylam (NASDAQ: ALNY ) have concluded the research and option phase of the companies 2014 RNAi therapeutics alliance in rare genetic diseases. The material collaboration terms for patisiran, vutrisiran (ALN-TTRsc02) and fitusiranwill continue unchange… read more...
Regeneron and Alnylam Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
via: PR Newswire at 2019-04-08 03:00:00:000
TARRYTOWN, N.Y. and CAMBRIDGE, Mass. , April 8, 2019 /PRNewswire/ -- Companies to also jointly advance select number of preclinical disease programs with targets expressed in the liver and treatments for C5 complement-mediated diseases Regeneron to invest $800 million thro… read more...
Alnylam and Regeneron Announce Broad Collaboration to Discover, Develop and Commercialize RNAi Therapeutics Focused on Ocular and Central Nervous System (CNS) Diseases
via: Business Wire at 2019-04-08 03:00:00:000
Companies to Also Jointly Advance Select Number of Preclinical Disease Programs with Targets Expressed in the Liver and Treatments for C5 Complement-Mediated Diseases Regeneron to Invest $800 million Through Upfront Cash and Equity Investment in Alnylam, with… read more...
Alnylam and Sanofi Conclude Research and Option Phase of 2014 RNAi Therapeutics Collaboration
via: Business Wire at 2019-04-07 21:00:00:000
Alnylam to Advance Selected Investigational Asset in an Undisclosed Rare Genetic Disease Through the End of IND-Enabling Studies Material Collaboration Terms for Patisiran, Vutrisiran, and Fitusiran, as Previously Announced, Remain Unchanged A… read more...
Healthcare Breakout Beat 2018 Forecast: How High Will It Go In 2019?
via: SeekingAlpha at 2019-04-05 07:28:20:000
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det… read more...
Healthcare Breakout Beat 2018 Forecast: How High Will It Go In 2019?
via: SeekingAlpha at 2019-04-05 07:28:20:000
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det… read more...
Healthcare Breakout Beat 2018 Forecast: How High Will It Go In 2019?
via: SeekingAlpha at 2019-04-05 07:28:20:000
From the Big Picture to Individual Stock Breakouts Last year I highlighted the Healthcare Biotech Sector Breakout and correctly forecasted "at least 20% gains in sector ETFs and even higher for many key biotech stocks in the near term." I believe the technical analysis that I will det… read more...
Key events next week - healthcare
via: SeekingAlpha at 2019-04-05 03:00:52:000
Noteworthy events during the week of April 7 - 13 for healthcare investors. More news on: Cigna Corporation, CVS Health Corporation, Humana Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2019-04-05 03:00:52:000
Noteworthy events during the week of April 7 - 13 for healthcare investors. More news on: Cigna Corporation, CVS Health Corporation, Humana Inc., Healthcare stocks news, , Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2019-04-05 03:00:52:000
Noteworthy events during the week of April 7 - 13 for healthcare investors. More news on: Cigna Corporation, CVS Health Corporation, Humana Inc., Healthcare stocks news, , Read more … read more...
Alnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress(TM)
via: Business Wire at 2019-03-27 03:00:00:000
-- Company to Host Conference Call on Saturday, April 13, 2019, at 8:00 am ET (2:00 pm CET) to Discuss Results -- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company and its collaborators will present at the European A… read more...
Alnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress(TM)
via: Business Wire at 2019-03-27 03:00:00:000
-- Company to Host Conference Call on Saturday, April 13, 2019, at 8:00 am ET (2:00 pm CET) to Discuss Results -- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company and its collaborators will present at the European A… read more...
Alnylam to Present Givosiran Phase 3 Data at the European Association for the Study of the Liver (EASL) International Liver Congress(TM)
via: Business Wire at 2019-03-27 03:00:00:000
-- Company to Host Conference Call on Saturday, April 13, 2019, at 8:00 am ET (2:00 pm CET) to Discuss Results -- Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company and its collaborators will present at the European A… read more...
Alnylam Is A Step Closer To Its Second Approved Drug
via: SeekingAlpha at 2019-03-14 04:00:00:000
The last twelve months havent been particularly good in terms of market performance for Alnylam Pharmaceuticals ( ALNY ), and that hasnt really changed much over the last three months either, as the shares continue to lag biotech indices. With top-line Phase III givosiran da… read more...
Alnylam Is A Step Closer To Its Second Approved Drug
via: SeekingAlpha at 2019-03-14 04:00:00:000
The last twelve months havent been particularly good in terms of market performance for Alnylam Pharmaceuticals ( ALNY ), and that hasnt really changed much over the last three months either, as the shares continue to lag biotech indices. With top-line Phase III givosiran da… read more...
Alnylam Is A Step Closer To Its Second Approved Drug
via: SeekingAlpha at 2019-03-14 04:00:00:000
The last twelve months havent been particularly good in terms of market performance for Alnylam Pharmaceuticals ( ALNY ), and that hasnt really changed much over the last three months either, as the shares continue to lag biotech indices. With top-line Phase III givosiran da… read more...
Alnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings
via: Business Wire at 2019-03-11 03:00:00:000
Company Expects to Initiate a Phase 1 Study in Mid-2019 Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Hea… read more...
Alnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings
via: Business Wire at 2019-03-11 03:00:00:000
Company Expects to Initiate a Phase 1 Study in Mid-2019 Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Hea… read more...
Alnylam Submits CTA Application for ALN-AGT, an Investigational RNAi Therapeutic for the Treatment of Hypertension in High Unmet Need Settings
via: Business Wire at 2019-03-11 03:00:00:000
Company Expects to Initiate a Phase 1 Study in Mid-2019 Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, announced today that the Company has submitted a clinical trial authorization (CTA) application to The Medicines and Hea… read more...
Alnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference
via: Business Wire at 2019-03-07 11:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Cowen & Company 39 th Annual Health Care Conference on Wednesday, March 13, 2019 at 11:20 am ET at the Marriott Copley Place in B… read more...
Alnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference
via: Business Wire at 2019-03-07 11:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Cowen & Company 39 th Annual Health Care Conference on Wednesday, March 13, 2019 at 11:20 am ET at the Marriott Copley Place in B… read more...
Alnylam to Webcast Presentation at Cowen & Company 39th Annual Health Care Conference
via: Business Wire at 2019-03-07 11:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Cowen & Company 39 th Annual Health Care Conference on Wednesday, March 13, 2019 at 11:20 am ET at the Marriott Copley Place in B… read more...
RNA Therapeutics: The Triumphant Return Of Biomolecular Mimetics
via: SeekingAlpha at 2019-03-07 07:36:51:000
Pain makes man think. Thought makes man wise. Wisdom makes life endurable. -John Patrick, Tea House of the August Moon There are few things in life more satisfying than the exhilarating thrill of discovery. Investing in ribonucleic acid ((RNA)) biotechnology does h… read more...
RNA Therapeutics: The Triumphant Return Of Biomolecular Mimetics
via: SeekingAlpha at 2019-03-07 07:36:51:000
Pain makes man think. Thought makes man wise. Wisdom makes life endurable. -John Patrick, Tea House of the August Moon There are few things in life more satisfying than the exhilarating thrill of discovery. Investing in ribonucleic acid ((RNA)) biotechnology does h… read more...
RNA Therapeutics: The Triumphant Return Of Biomolecular Mimetics
via: SeekingAlpha at 2019-03-07 07:36:51:000
Pain makes man think. Thought makes man wise. Wisdom makes life endurable. -John Patrick, Tea House of the August Moon There are few things in life more satisfying than the exhilarating thrill of discovery. Investing in ribonucleic acid ((RNA)) biotechnology does h… read more...
"Encouraging" safety profile for Alnylam's givosiran not so encouraging, shares down 3%
via: SeekingAlpha at 2019-03-06 07:22:24:000
Alnylam Pharmaceuticals ( ALNY -3.4% ) is down on 40% higher volume following its announcement of positive results from a Phase 3 clinical trial evaluating RNAi therapeutic givosiran in patients with acute hepatic porphyria. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stock… read more...
NIO, GE and WLTW among premarket losers
via: SeekingAlpha at 2019-03-06 04:20:07:000
NIO (NYSE: NIO ) -20% on Q4 earnings . More news on: NIO, SELLAS Life Sciences Group, Inc., Qutoutiao, Stocks on the move, Read more … read more...
Alnylam's givosiran successful in late-stage AHP study
via: SeekingAlpha at 2019-03-06 02:27:31:000
Results from a Phase 3 clinical trial, ENVISION , evaluating Alnylam Pharmaceuticals' (NASDAQ: ALNY ) givosiran in patients with acute hepatic porphyria (AHP) showed a treatment benefit. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Alnylam Reports Positive Topline Results from ENVISION Phase 3 Study of Givosiran in Acute Hepatic Porphyria
via: Business Wire at 2019-03-06 02:00:00:000
Givosiran Meets Primary and Majority of Secondary Endpoints, with Significant Reduction in Annualized Rate of Composite Porphyria Attacks Relative to Placebo Alnylam Intends to Complete Filing of New Drug Application (NDA) and Marketing Authorisation Applicat… read more...
Cowen sees 94% upside in Aurora Cannabis in premarket analyst action
via: SeekingAlpha at 2019-03-05 02:55:48:000
Aurora Cannabis (NYSE: ACB ) initiated with Outperform rating and $14 (94% upside) price target at Cowen and Company citing its large cultivation footprint and geographic diversity. Shares up 3% premarket. More news on: Aurora Cannabis Inc., Gossamer Bio, Alnylam Pharmaceutical… read more...
Alnylam Announces Recipients of First Annual Advocacy for Impact Grants Program
via: Business Wire at 2019-02-28 07:00:00:000
Competitive Grants Program Recognizes New Projects that Impact the ATTR Amyloidosis and Acute Hepatic Porphyria Patient Communities Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced support for seven patient adv… read more...
Alnylam Announces Recipients of First Annual Advocacy for Impact Grants Program
via: Business Wire at 2019-02-28 02:00:00:000
Competitive Grants Program Recognizes New Projects that Impact the ATTR Amyloidosis and Acute Hepatic Porphyria Patient Communities Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced support for seven patient adv… read more...
Alnylam Announces Recipients of First Annual Advocacy for Impact Grants Program
via: Business Wire at 2019-02-28 02:00:00:000
Competitive Grants Program Recognizes New Projects that Impact the ATTR Amyloidosis and Acute Hepatic Porphyria Patient Communities Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced support for seven patient adv… read more...
Alnylam As A Strategic Investment
via: SeekingAlpha at 2019-02-21 08:51:11:000
Alnylam Pharmaceuticals (ALNY) is now a commercial-stage biotechnology pharmaceutical company. Its drug for treating the rare disease ATTR amyloidosis, Onpattro, is the first drug using a specific type of RNA therapy, RNAi (RNA interference), to be approved by the FDA. I consider Alnylam to … read more...
Alnylam As A Strategic Investment
via: SeekingAlpha at 2019-02-21 08:51:11:000
Alnylam Pharmaceuticals (ALNY) is now a commercial-stage biotechnology pharmaceutical company. Its drug for treating the rare disease ATTR amyloidosis, Onpattro, is the first drug using a specific type of RNA therapy, RNAi (RNA interference), to be approved by the FDA. I consider Alnylam to … read more...
Alnylam As A Strategic Investment
via: SeekingAlpha at 2019-02-21 08:51:11:000
Alnylam Pharmaceuticals (ALNY) is now a commercial-stage biotechnology pharmaceutical company. Its drug for treating the rare disease ATTR amyloidosis, Onpattro, is the first drug using a specific type of RNA therapy, RNAi (RNA interference), to be approved by the FDA. I consider Alnylam to … read more...
FDA OKs Novo's Esperoct for hemophilia A
via: SeekingAlpha at 2019-02-19 12:58:07:000
The FDA approves Novo Nordisk's ( NVO +0.3% ) long-acting factor VIII replacement therapy ESPEROCT (turoctocog alfa pegol) for adults and children with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes … read more...
FDA OKs Novo's Esperoct for hemophilia A
via: SeekingAlpha at 2019-02-19 12:58:07:000
The FDA approves Novo Nordisk's ( NVO +0.3% ) long-acting factor VIII replacement therapy ESPEROCT (turoctocog alfa pegol) for adults and children with hemophilia A for routine prophylaxis to reduce the frequency of bleeding episodes, on-demand treatment and control of bleeding episodes … read more...
Biotech Bonanza: The Mergers And Acquisitions Theme
via: SeekingAlpha at 2019-02-13 14:55:11:000
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...
Biotech Bonanza: The Mergers And Acquisitions Theme
via: SeekingAlpha at 2019-02-13 14:55:11:000
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...
Biotech Bonanza: The Mergers And Acquisitions Theme
via: SeekingAlpha at 2019-02-13 14:55:11:000
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an… read more...
Trump's China Caution Deflates Investors On Edge Over Trade (Wall Street Breakfast Podcast)
via: SeekingAlpha at 2019-02-08 07:29:50:000
Today's Top Stories: Trump's China caution deflates investors on edge over trade; Trump to ban China telecom equipment over cyber threats; and Jeff Bezos accuses National Enquirer of blackmail. If you are interested in listening to Wall Street Breakfast to start your day, look for us … read more...
Trump's China Caution Deflates Investors On Edge Over Trade (Wall Street Breakfast Podcast)
via: SeekingAlpha at 2019-02-08 07:29:50:000
Today's Top Stories: Trump's China caution deflates investors on edge over trade; Trump to ban China telecom equipment over cyber threats; and Jeff Bezos accuses National Enquirer of blackmail. If you are interested in listening to Wall Street Breakfast to start your day, look for us … read more...
Trump's China Caution Deflates Investors On Edge Over Trade (Wall Street Breakfast Podcast)
via: SeekingAlpha at 2019-02-08 07:29:50:000
Today's Top Stories: Trump's China caution deflates investors on edge over trade; Trump to ban China telecom equipment over cyber threats; and Jeff Bezos accuses National Enquirer of blackmail. If you are interested in listening to Wall Street Breakfast to start your day, look for us … read more...
Trump's China Caution Deflates Investors On Edge Over Trade (Wall Street Breakfast Podcast)
via: SeekingAlpha at 2019-02-08 07:29:50:000
Today's Top Stories: Trump's China caution deflates investors on edge over trade; Trump to ban China telecom equipment over cyber threats; and Jeff Bezos accuses National Enquirer of blackmail. If you are interested in listening to Wall Street Breakfast to start your day, look for us … read more...
Trump's China Caution Deflates Investors On Edge Over Trade (Wall Street Breakfast Podcast)
via: SeekingAlpha at 2019-02-08 07:29:50:000
Today's Top Stories: Trump's China caution deflates investors on edge over trade; Trump to ban China telecom equipment over cyber threats; and Jeff Bezos accuses National Enquirer of blackmail. If you are interested in listening to Wall Street Breakfast to start your day, look for us … read more...
Wall Street Breakfast: Trump's China Caution Deflates Investors On Edge Over Trade
via: SeekingAlpha at 2019-02-08 06:12:00:000
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). U.S. stock futures point to additional losses after President Trump said yesterday that he would not meet with Chi… read more...
Wall Street Breakfast: Trump's China Caution Deflates Investors On Edge Over Trade
via: SeekingAlpha at 2019-02-08 06:12:00:000
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). U.S. stock futures point to additional losses after President Trump said yesterday that he would not meet with Chi… read more...
Wall Street Breakfast: Trump's China Caution Deflates Investors On Edge Over Trade
via: SeekingAlpha at 2019-02-08 06:12:00:000
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). U.S. stock futures point to additional losses after President Trump said yesterday that he would not meet with Chi… read more...
Wall Street Breakfast: Trump's China Caution Deflates Investors On Edge Over Trade
via: SeekingAlpha at 2019-02-08 06:12:00:000
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). U.S. stock futures point to additional losses after President Trump said yesterday that he would not meet with Chi… read more...
Wall Street Breakfast: Trump's China Caution Deflates Investors On Edge Over Trade
via: SeekingAlpha at 2019-02-08 06:12:00:000
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on iTunes , Stitcher and SoundCloud (click the highlighted links). U.S. stock futures point to additional losses after President Trump said yesterday that he would not meet with Chi… read more...
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-02-07 22:46:12:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2018 Earnings Conference Call February 07, 2019 4:30 PM ET Company Participants Christine Lindenboom - Vice President of Investor Relations & Corporate Communications John Maraganore - Chief Executive Officer Barry Greene - President … read more...
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-02-07 22:46:12:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2018 Earnings Conference Call February 07, 2019 4:30 PM ET Company Participants Christine Lindenboom - Vice President of Investor Relations & Corporate Communications John Maraganore - Chief Executive Officer Barry Greene - President … read more...
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-02-07 22:46:12:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2018 Earnings Conference Call February 07, 2019 4:30 PM ET Company Participants Christine Lindenboom - Vice President of Investor Relations & Corporate Communications John Maraganore - Chief Executive Officer Barry Greene - President … read more...
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-02-07 22:46:12:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2018 Earnings Conference Call February 07, 2019 4:30 PM ET Company Participants Christine Lindenboom - Vice President of Investor Relations & Corporate Communications John Maraganore - Chief Executive Officer Barry Greene - President … read more...
Alnylam Pharmaceuticals, Inc. (ALNY) CEO John Maraganore on Q4 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2019-02-07 22:46:12:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2018 Earnings Conference Call February 07, 2019 4:30 PM ET Company Participants Christine Lindenboom - Vice President of Investor Relations & Corporate Communications John Maraganore - Chief Executive Officer Barry Greene - President … read more...
Alnylam Pharmaceuticals, Inc. 2018 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2019-02-07 17:03:51:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2018 Q4 earnings Read more … read more...
Alnylam Q4 Onpattro sales $12.1M
via: SeekingAlpha at 2019-02-07 16:17:41:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) Q4 results ($M): Revenues: 21.0 (-44.6%); ONPATTRO sales: 12.1. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...
Alnylam Pharmaceuticals beats by $0.38, beats on revenue
via: SeekingAlpha at 2019-02-07 16:03:17:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q4 Non-GAAP EPS of -$1.82 beats by $0.38 ; GAAP EPS of -$2.09 beats by $0.11 . Revenue of $21M (-44.6% Y/Y) beats by $5.53M . Press Release More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, … read more...
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Recent Period Activity
via: Business Wire at 2019-02-07 16:00:00:000
Achieved Fourth Quarter 2018 ONPATTRO Global Net Product Revenues of $12.1 Million, with Over 200 Patients on Commercial Product in U.S. and EU as of Year-End 2018 Obtained Regulatory Alignment on APOLLO-B Phase 3 Study of Patisiran in ATTR Amyloidosis … read more...
Alnylam Pharmaceuticals: Factors Of Influence In 2019, Key Indicators And Opportunity
via: SeekingAlpha at 2019-02-07 11:42:52:000
In the first half of January, Alnylam announced preliminary Q4 sales for Onpattro (patisiran), the companys single commercialized drug. In addition, in mid-January, the firm declared a public offering of 5 million shares to cover further development and commercialization of patisiran a… read more...
Alnylam Pharmaceuticals Q4 2018 Earnings Preview
via: SeekingAlpha at 2019-02-06 17:35:30:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) is scheduled to announce Q4 earnings results on Thursday, February 7th, after market close. The consensus EPS Estimate is -$2.20 (-83.3% Y/Y) and the consensus Revenue Estimate is $15.47M (-59.2% Y/Y). Over the last 2 years, ALNY has beaten EPS … read more...
Notable earnings after Thursday's close
via: SeekingAlpha at 2019-02-06 17:35:01:000
ALNY , ANGI , ASYS , ATEN , ATGE , BECN , BHE , BKH , BRS , CARB , CBL , COLM , CSL , DXC , EEFT , EGAN , EHC , ESE , EXPE , FET , FISV , FSCT , FTV , FWRD , G , HUBG , IAC , KN , LGF.A , LGND , MAT , MHK , MOBL , MSI , MT , MTD , MTW , NCR , NR , NUA… read more...
Alnylam Announces Publication of Phase 1 Givosiran Data in The New England Journal of Medicine
via: Business Wire at 2019-02-06 17:00:00:000
Givosiran Associated with Substantial and Sustained Lowering of Neurotoxic Heme Synthesis Intermediates Implicated in Acute Intermittent Porphyria Givosiran also Associated with Reduced Rate of Porphyria Attacks and Hemin Use Topline Ph… read more...
Alnylam to Webcast Presentations at Upcoming February Investor Conferences
via: Business Wire at 2019-02-04 16:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 21 st Annual BIO CEO & Investor Conference on Monday, February 11, 2019 at 1:30 pm ET at the Marriott… read more...
Alnylam to Webcast Presentations at Upcoming February Investor Conferences
via: Business Wire at 2019-02-04 16:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 21 st Annual BIO CEO & Investor Conference on Monday, February 11, 2019 at 1:30 pm ET at the Marriott… read more...
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results
via: Business Wire at 2019-01-31 16:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2018 on Thursday, February 7, 2019, after the U.S. financial markets close. Management will pro… read more...
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results
via: Business Wire at 2019-01-31 16:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2018 on Thursday, February 7, 2019, after the U.S. financial markets close. Management will pro… read more...
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2018 Financial Results
via: Business Wire at 2019-01-31 16:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2018 on Thursday, February 7, 2019, after the U.S. financial markets close. Management will pro… read more...
Jefferies bearish on biotechs, sees 6% near-term downside
via: SeekingAlpha at 2019-01-23 14:05:04:000
Jefferies healthcare strategist Jared Holtz is a short-term biotech bear saying that profit-taking "makes sense" through this earnings season considering the sector's market-leading performance so far this year. He thinks the SPDR S&P Biotech ETF ( XBI -1.3% ) could drop to $75 ( -6% )… read more...
Jefferies bearish on biotechs, sees 6% near-term downside
via: SeekingAlpha at 2019-01-23 14:05:04:000
Jefferies healthcare strategist Jared Holtz is a short-term biotech bear saying that profit-taking "makes sense" through this earnings season considering the sector's market-leading performance so far this year. He thinks the SPDR S&P Biotech ETF ( XBI -1.3% ) could drop to $75 ( -6% )… read more...
Jefferies bearish on biotechs, sees 6% near-term downside
via: SeekingAlpha at 2019-01-23 14:05:04:000
Jefferies healthcare strategist Jared Holtz is a short-term biotech bear saying that profit-taking "makes sense" through this earnings season considering the sector's market-leading performance so far this year. He thinks the SPDR S&P Biotech ETF ( XBI -1.3% ) could drop to $75 ( -6% )… read more...
UBS likes Lilly in premarket analyst action
via: SeekingAlpha at 2019-01-23 08:47:03:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Neutral rating at UBS. More news on: Alnylam Pharmaceuticals, Inc., Atara Biotherapeutics, Elanco, Healthcare stocks news, Stocks on the move, , Read more … read more...
UBS likes Lilly in premarket analyst action
via: SeekingAlpha at 2019-01-23 08:47:03:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Neutral rating at UBS. More news on: Alnylam Pharmaceuticals, Inc., Atara Biotherapeutics, Elanco, Healthcare stocks news, Stocks on the move, , Read more … read more...
UBS likes Lilly in premarket analyst action
via: SeekingAlpha at 2019-01-23 08:47:03:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) initiated with Neutral rating at UBS. More news on: Alnylam Pharmaceuticals, Inc., Atara Biotherapeutics, Elanco, Healthcare stocks news, Stocks on the move, , Read more … read more...
Pfizer Looks To Move Tafamidis Forward With Priority Review
via: SeekingAlpha at 2019-01-22 11:27:05:000
Recently, Pfizer ( PFE ) announced that it had successfully submitted both its New Drug Applications ((NDA)) for tafamidis. The two applications are for each version of the drug being approved to treat patients with a rare disease known as transthyretin amyloid cardiomyopathy (ATTR-CM). … read more...
FDA to beef up cell and gene therapy staff
via: SeekingAlpha at 2019-01-15 13:17:05:000
Citing the 800 active INDs for cell therapy and gene therapy candidates and the expectation that it will be receiving more that 200 INDs each year by 2020, FDA Commission Scott Gottlieb, M.D., outlines the agency's initiatives to support timely review and to enable the approval of 10 - 20 … read more...
FDA to beef up cell and gene therapy staff
via: SeekingAlpha at 2019-01-15 13:17:05:000
Citing the 800 active INDs for cell therapy and gene therapy candidates and the expectation that it will be receiving more that 200 INDs each year by 2020, FDA Commission Scott Gottlieb, M.D., outlines the agency's initiatives to support timely review and to enable the approval of 10 - 20 … read more...
FDA to beef up cell and gene therapy staff
via: SeekingAlpha at 2019-01-15 13:17:05:000
Citing the 800 active INDs for cell therapy and gene therapy candidates and the expectation that it will be receiving more that 200 INDs each year by 2020, FDA Commission Scott Gottlieb, M.D., outlines the agency's initiatives to support timely review and to enable the approval of 10 - 20 … read more...
SHW, BIOC and ALNY among premarket losers
via: SeekingAlpha at 2019-01-15 09:10:44:000
Biocept (NASDAQ: BIOC ) -20% . More news on: Biocept, Inc., PG&E Corporation, Stellar Biotechnologies Inc., Stocks on the move, , Read more … read more...
SHW, BIOC and ALNY among premarket losers
via: SeekingAlpha at 2019-01-15 09:10:44:000
Biocept (NASDAQ: BIOC ) -20% . More news on: Biocept, Inc., PG&E Corporation, Stellar Biotechnologies Inc., Stocks on the move, , Read more … read more...
SHW, BIOC and ALNY among premarket losers
via: SeekingAlpha at 2019-01-15 09:10:44:000
Biocept (NASDAQ: BIOC ) -20% . More news on: Biocept, Inc., PG&E Corporation, Stellar Biotechnologies Inc., Stocks on the move, , Read more … read more...
Alnylam Pharmaceuticals lower 4% on pricing of public offering of common stock
via: SeekingAlpha at 2019-01-15 05:56:51:000
Alnylam Pharmaceuticals ( ALNY ) announced pricing of an underwritten public offering of 5M common shares at $77.50/share for gross proceeds ~$387.5M. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Alnylam Pharmaceuticals lower 4% on pricing of public offering of common stock
via: SeekingAlpha at 2019-01-15 05:56:51:000
Alnylam Pharmaceuticals ( ALNY ) announced pricing of an underwritten public offering of 5M common shares at $77.50/share for gross proceeds ~$387.5M. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Alnylam Pharmaceuticals lower 4% on pricing of public offering of common stock
via: SeekingAlpha at 2019-01-15 05:56:51:000
Alnylam Pharmaceuticals ( ALNY ) announced pricing of an underwritten public offering of 5M common shares at $77.50/share for gross proceeds ~$387.5M. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Alnylam Pharmaceuticals Prices Public Offering of Common Stock
via: Business Wire at 2019-01-14 21:13:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $77.50 per share. The gross proceeds to Alnylam from the offering, before … read more...
Alnylam Pharmaceuticals Prices Public Offering of Common Stock
via: Business Wire at 2019-01-14 21:13:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $77.50 per share. The gross proceeds to Alnylam from the offering, before … read more...
Alnylam Pharmaceuticals Prices Public Offering of Common Stock
via: Business Wire at 2019-01-14 21:13:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the pricing of an underwritten public offering of 5,000,000 shares of its common stock at a public offering price of $77.50 per share. The gross proceeds to Alnylam from the offering, before … read more...
After hours movers and shakers
via: SeekingAlpha at 2019-01-14 17:37:20:000
Gainers: BGFV +10.9% . PLAY +6.1% . FTNW +5.2% . AZN +2.0% . FTR +1.9% . More news on: Big 5 Sporting Goods Corporation, Dave & Buster's Entertainment, Inc., FTE Networks, Inc., Stocks on the move, , Read more … read more...
Alnylam Pharmaceuticals Announces Proposed Public Offering of Common Stock
via: Business Wire at 2019-01-14 16:04:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the commencement of an underwritten public offering of 5,000,000 shares of its common stock. In addition, Alnylam has granted the underwriter a 30-day option to purchase up to an additional… read more...
Does The Bull Survive? Stock Market Outlook 2019
via: SeekingAlpha at 2019-01-11 17:01:16:000
Market Pulse The year 2018 will be remembered as the year when downside volatility thundered into the market in striking contrast to 2017 when stock market volatility was so meek that it subsided to a level below that of bonds for the first time. The final month of 2018 was different. The … read more...
Does The Bull Survive? Stock Market Outlook 2019
via: SeekingAlpha at 2019-01-11 17:01:16:000
Market Pulse The year 2018 will be remembered as the year when downside volatility thundered into the market in striking contrast to 2017 when stock market volatility was so meek that it subsided to a level below that of bonds for the first time. The final month of 2018 was different. The … read more...
Does The Bull Survive? Stock Market Outlook 2019
via: SeekingAlpha at 2019-01-11 17:01:16:000
Market Pulse The year 2018 will be remembered as the year when downside volatility thundered into the market in striking contrast to 2017 when stock market volatility was so meek that it subsided to a level below that of bonds for the first time. The final month of 2018 was different. The … read more...
Alnylam Reports Improved Onpattro Sales Going Into A Busy Year
via: SeekingAlpha at 2019-01-08 19:45:20:000
Alnylam's ( ALNY ) shareholders have been holding on in the hope of some good news and the company finally provided some with the start of J.P. Morgans annual healthcare conference. A stronger quarterly result for the companys lone commercialized drug (Onpattro) should restor… read more...
Alnylam Reports Improved Onpattro Sales Going Into A Busy Year
via: SeekingAlpha at 2019-01-08 19:45:20:000
Alnylam's ( ALNY ) shareholders have been holding on in the hope of some good news and the company finally provided some with the start of J.P. Morgans annual healthcare conference. A stronger quarterly result for the companys lone commercialized drug (Onpattro) should restor… read more...
Alnylam Pharmaceuticals (ALNY) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-01-07 15:16:20:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Alnylam Pharmaceuticals (ALNY) Investor Presentation - Slideshow
via: SeekingAlpha at 2019-01-07 15:16:20:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Alnylam up 9% on Q4 Onpattro sales
via: SeekingAlpha at 2019-01-07 13:02:16:000
Alnylam Pharmaceuticals ( ALNY +9.3% ) is up on below-average volume on the heels of its announcement of preliminary Q4 2018 results. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Alnylam up 9% on Q4 Onpattro sales
via: SeekingAlpha at 2019-01-07 13:02:16:000
Alnylam Pharmaceuticals ( ALNY +9.3% ) is up on below-average volume on the heels of its announcement of preliminary Q4 2018 results. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19
via: SeekingAlpha at 2019-01-07 10:13:49:000
Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&P Biotech ETF ( XBI +4.8% ) is up… read more...
Biotechs up out the gate on Lilly/Loxo tie-up and start of JPM19
via: SeekingAlpha at 2019-01-07 10:13:49:000
Healthcare investors are enjoying a rousing start to the week after Eli Lilly announced its takeover of Loxo Oncology and the release of a multitude of preliminary 2018 results for presenters at JPMorgan's 2019 Healthcare Conference (JPM19). The SPDR S&P Biotech ETF ( XBI +4.8% ) is up… read more...
Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates
via: Business Wire at 2019-01-07 08:00:00:000
Achieved Fourth Quarter 2018 ONPATTRO Unaudited Global Net Product Revenues of $11-12 Million Over 200 Patients on Commercial ONPATTRO in U.S. and EU from Launch Through Year-End 2018 Maintained Strong Balance Sheet with Unaudited Year-… read more...
Alnylam Announces Unaudited Fourth Quarter 2018 Global Revenues for ONPATTRO® (patisiran) and Provides Additional Commercial Updates
via: Business Wire at 2019-01-07 08:00:00:000
Achieved Fourth Quarter 2018 ONPATTRO Unaudited Global Net Product Revenues of $11-12 Million Over 200 Patients on Commercial ONPATTRO in U.S. and EU from Launch Through Year-End 2018 Maintained Strong Balance Sheet with Unaudited Year-… read more...
CNBC article highlights $35B market opportunity of NASH drugs
via: SeekingAlpha at 2018-12-31 11:59:50:000
CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal… read more...
CNBC article highlights $35B market opportunity of NASH drugs
via: SeekingAlpha at 2018-12-31 11:59:50:000
CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal… read more...
CNBC article highlights $35B market opportunity of NASH drugs
via: SeekingAlpha at 2018-12-31 11:59:50:000
CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal… read more...
CNBC article highlights $35B market opportunity of NASH drugs
via: SeekingAlpha at 2018-12-31 11:59:50:000
CNBC reports that nonalcoholic steatohepatitis or NASH is "next big thing" for drug makers, a potential market of $35B or more if pharma/biotech firms can successfully navigate the regulatory process, a task none has accomplished to date. More news on: Intercept Pharmaceuticals, Madrigal… read more...
Ionis: Performs Great In A Volatile Market
via: SeekingAlpha at 2018-12-31 08:30:56:000
Note: this is a follow-on analysis to Ionis: Good Value With Non-Binary Upside article published on Seeking Alpha in February 2018. Thesis Ionis ( IONS ) stock performance in 2018 was satisfactory, given that both IBB ( IBB ) and S&P 500 ( SPY ) lost 16% and 12% YTD, respectively… read more...
Ionis: Performs Great In A Volatile Market
via: SeekingAlpha at 2018-12-31 08:30:56:000
Note: this is a follow-on analysis to Ionis: Good Value With Non-Binary Upside article published on Seeking Alpha in February 2018. Thesis Ionis ( IONS ) stock performance in 2018 was satisfactory, given that both IBB ( IBB ) and S&P 500 ( SPY ) lost 16% and 12% YTD, respectively… read more...
Ionis: Performs Great In A Volatile Market
via: SeekingAlpha at 2018-12-31 08:30:56:000
Note: this is a follow-on analysis to Ionis: Good Value With Non-Binary Upside article published on Seeking Alpha in February 2018. Thesis Ionis ( IONS ) stock performance in 2018 was satisfactory, given that both IBB ( IBB ) and S&P 500 ( SPY ) lost 16% and 12% YTD, respectively… read more...
Ionis: Performs Great In A Volatile Market
via: SeekingAlpha at 2018-12-31 08:30:56:000
Note: this is a follow-on analysis to Ionis: Good Value With Non-Binary Upside article published on Seeking Alpha in February 2018. Thesis Ionis ( IONS ) stock performance in 2018 was satisfactory, given that both IBB ( IBB ) and S&P 500 ( SPY ) lost 16% and 12% YTD, respectively… read more...
Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference
via: Business Wire at 2018-12-28 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 10:30 am PT (1:30 pm ET) at The Westin St. Francis in Sa… read more...
Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference
via: Business Wire at 2018-12-28 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 10:30 am PT (1:30 pm ET) at The Westin St. Francis in Sa… read more...
Alnylam to Webcast Presentation at 37th Annual J.P. Morgan Healthcare Conference
via: Business Wire at 2018-12-28 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 37 th Annual J.P. Morgan Healthcare Conference on Monday, January 7, 2019 at 10:30 am PT (1:30 pm ET) at The Westin St. Francis in Sa… read more...
Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders
via: Business Wire at 2018-12-20 17:13:00:000
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) have sued Alnylam officers and directors for alleged violations of the Securities Exchange Act of 1934 between February 15, 2018 and September 12, 2018. Alnyl… read more...
Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders
via: Business Wire at 2018-12-20 17:13:00:000
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) have sued Alnylam officers and directors for alleged violations of the Securities Exchange Act of 1934 between February 15, 2018 and September 12, 2018. Alnyl… read more...
Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders
via: Business Wire at 2018-12-20 17:13:00:000
Shareholder rights law firm Robbins Arroyo LLP reminds shareholders that purchasers of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) have sued Alnylam officers and directors for alleged violations of the Securities Exchange Act of 1934 between February 15, 2018 and September 12, 2018. Alnyl… read more...
Biotech Bonanza: 2019 Outlook On An Uphill Battle
via: SeekingAlpha at 2018-12-20 14:47:33:000
Biotech Pulse The stock market was on track for a solid double-digit return performance in 2018, until it entered the final quarter. The performance cart has been rattling ever since as the stock market's perception of risk has risen dramatically, leading to a sharp erosion of returns. While… read more...
Biotech Bonanza: 2019 Outlook On An Uphill Battle
via: SeekingAlpha at 2018-12-20 14:47:33:000
Biotech Pulse The stock market was on track for a solid double-digit return performance in 2018, until it entered the final quarter. The performance cart has been rattling ever since as the stock market's perception of risk has risen dramatically, leading to a sharp erosion of returns. While… read more...
Biotech Bonanza: 2019 Outlook On An Uphill Battle
via: SeekingAlpha at 2018-12-20 14:47:33:000
Biotech Pulse The stock market was on track for a solid double-digit return performance in 2018, until it entered the final quarter. The performance cart has been rattling ever since as the stock market's perception of risk has risen dramatically, leading to a sharp erosion of returns. While… read more...
Credit Suisse sees 18% upside in Abbott in premarket analyst action
via: SeekingAlpha at 2018-12-18 08:05:22:000
Abbott (NYSE: ABT ) initiated with Outperform rating and $82 (18% upside) price target at Credit Suisse. More news on: Abbott Laboratories, Alnylam Pharmaceuticals, Inc., Baxter International Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...
Credit Suisse sees 18% upside in Abbott in premarket analyst action
via: SeekingAlpha at 2018-12-18 08:05:22:000
Abbott (NYSE: ABT ) initiated with Outperform rating and $82 (18% upside) price target at Credit Suisse. More news on: Abbott Laboratories, Alnylam Pharmaceuticals, Inc., Baxter International Inc, Healthcare stocks news, Stocks on the move, , Read more … read more...
Alnylam settles litigation with Silence Therapeutics
via: SeekingAlpha at 2018-12-10 06:52:45:000
Alnylam Pharmaceuticals(NASDAQ: ALNY ) has resolved all litigation worldwide with Silence Therapeutics, therebyavoiding the costs and distraction associated with continued litigation in multiple countries. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, … read more...
Alnylam settles litigation with Silence Therapeutics
via: SeekingAlpha at 2018-12-10 06:52:45:000
Alnylam Pharmaceuticals(NASDAQ: ALNY ) has resolved all litigation worldwide with Silence Therapeutics, therebyavoiding the costs and distraction associated with continued litigation in multiple countries. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, … read more...
Alnylam Announces Settlement of Litigation with Silence Therapeutics
via: Business Wire at 2018-12-10 02:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has resolved all litigation worldwide with Silence Therapeutics. The settlement allows Alnylam to avoid the costs and distraction associated with continued litigation in multip… read more...
Alnylam Announces Settlement of Litigation with Silence Therapeutics
via: Business Wire at 2018-12-10 02:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has resolved all litigation worldwide with Silence Therapeutics. The settlement allows Alnylam to avoid the costs and distraction associated with continued litigation in multip… read more...
Alnylam Pharmaceuticals Tries To Rally The Troops With A Blizzard Of New R&D Candidates
via: SeekingAlpha at 2018-12-08 00:23:30:000
There are two criticisms youll never read about Alnylam ( ALNY ) that management is insufficiently promotional of the company, and that it doesnt have enough pipeline candidates/ideas. Always a company with many irons in the fire, Alnylam hosted an R&D day Thursd… read more...
Alnylam Pharmaceuticals Tries To Rally The Troops With A Blizzard Of New R&D Candidates
via: SeekingAlpha at 2018-12-08 00:23:30:000
There are two criticisms youll never read about Alnylam ( ALNY ) that management is insufficiently promotional of the company, and that it doesnt have enough pipeline candidates/ideas. Always a company with many irons in the fire, Alnylam hosted an R&D day Thursd… read more...
Moderna IPO: Very Expensive
via: SeekingAlpha at 2018-12-06 09:02:42:000
Moderna (MRNA) seems too expensive with an enterprise value of $7.461 billion. Other competitors report enterprise value of $7.61-$10 billion with a more advanced stage of development. Competitors at an early stage of development, like Moderna, trade with an enterprise value of $1.28 billion. … read more...
Moderna IPO: Very Expensive
via: SeekingAlpha at 2018-12-06 09:02:42:000
Moderna (MRNA) seems too expensive with an enterprise value of $7.461 billion. Other competitors report enterprise value of $7.61-$10 billion with a more advanced stage of development. Competitors at an early stage of development, like Moderna, trade with an enterprise value of $1.28 billion. … read more...
Alnylam updates on pipeline at R&D Day
via: SeekingAlpha at 2018-12-06 08:57:53:000
At its R&D Day in New York today, Alnylam Pharmaceuticals (NASDAQ: ALNY ) will discuss its pipeline objectives and patisiran commercial plan for next year. Highlights: More news on: Alnylam Pharmaceuticals, Inc., The Medicines Company, Healthcare stocks news, Read more … read more...
Alnylam updates on pipeline at R&D Day
via: SeekingAlpha at 2018-12-06 08:57:53:000
At its R&D Day in New York today, Alnylam Pharmaceuticals (NASDAQ: ALNY ) will discuss its pipeline objectives and patisiran commercial plan for next year. Highlights: More news on: Alnylam Pharmaceuticals, Inc., The Medicines Company, Healthcare stocks news, Read more … read more...
Alnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day
via: Business Wire at 2018-12-06 07:00:00:000
In 2019, Alnylam Will Continue ONPATTRO Global Launch and Advance Late-Stage Pipeline of Wholly Owned and Partnered Programs with: Five Phase 3 Programs; Three Phase 3 Program Readouts; and Two New Drug Application (NDA) Filings Initiates Rolling Subm… read more...
Alnylam Provides R&D Updates and Announces 2019 Product and Pipeline Goals at R&D Day
via: Business Wire at 2018-12-06 07:00:00:000
In 2019, Alnylam Will Continue ONPATTRO Global Launch and Advance Late-Stage Pipeline of Wholly Owned and Partnered Programs with: Five Phase 3 Programs; Three Phase 3 Program Readouts; and Two New Drug Application (NDA) Filings Initiates Rolling Subm… read more...
Alnylam to Webcast R&D Day
via: Business Wire at 2018-11-29 08:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the Companys website, www.alnylam.com , on the morning of December 6, 2018… read more...
Alnylam to Webcast R&D Day
via: Business Wire at 2018-11-29 08:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the Companys website, www.alnylam.com , on the morning of December 6, 2018… read more...
Alnylam to Webcast R&D Day
via: Business Wire at 2018-11-29 08:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will webcast its upcoming R&D Day, including a live video stream, on the Investors section of the Companys website, www.alnylam.com , on the morning of December 6, 2018… read more...
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
via: Business Wire at 2018-11-26 08:00:00:000
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of t… read more...
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
via: Business Wire at 2018-11-26 08:00:00:000
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of t… read more...
DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
via: Business Wire at 2018-11-26 08:00:00:000
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of t… read more...
Vir Bio launches Phase 1/2 study of RNAi therapeutic for HBV
via: SeekingAlpha at 2018-11-26 07:50:19:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that licensee Vir Biotechnology has initiated a Phase 1/2 clinical trial evaluating RNAi therapeutic VIR-2218 for the treatment of chronic hepatitis B virus (HBV) infection. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks… read more...
Vir Bio launches Phase 1/2 study of RNAi therapeutic for HBV
via: SeekingAlpha at 2018-11-26 07:50:19:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that licensee Vir Biotechnology has initiated a Phase 1/2 clinical trial evaluating RNAi therapeutic VIR-2218 for the treatment of chronic hepatitis B virus (HBV) infection. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks… read more...
Vir Bio launches Phase 1/2 study of RNAi therapeutic for HBV
via: SeekingAlpha at 2018-11-26 07:50:19:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that licensee Vir Biotechnology has initiated a Phase 1/2 clinical trial evaluating RNAi therapeutic VIR-2218 for the treatment of chronic hepatitis B virus (HBV) infection. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks… read more...
Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
via: Business Wire at 2018-11-26 07:00:00:000
-- Novel investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection -- Subject dosing commenced Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, inve… read more...
Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
via: Business Wire at 2018-11-26 07:00:00:000
-- Novel investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection -- Subject dosing commenced Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, inve… read more...
Vir Biotechnology and Alnylam Pharmaceuticals Initiate Phase 1/2 Study of VIR-2218
via: Business Wire at 2018-11-26 07:00:00:000
-- Novel investigational RNAi therapeutic for the treatment of chronic hepatitis B virus (HBV) infection -- Subject dosing commenced Vir Biotechnology, Inc. and Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) today announced the initiation of a Phase 1/2 study of VIR-2218, a novel, inve… read more...
Viking Therapeutics Won't Live Up To The Hype
via: SeekingAlpha at 2018-11-26 05:00:00:000
NASH an introduction Fatty deposits and mild fibrosis in non-alcoholic fatty liver disease. Source NASH short for non-alcoholic steatohepatitis has been a magnet for biotech investors over the past few years. NASH designates the most severe form of non-alc… read more...
Viking Therapeutics Won't Live Up To The Hype
via: SeekingAlpha at 2018-11-26 05:00:00:000
NASH an introduction Fatty deposits and mild fibrosis in non-alcoholic fatty liver disease. Source NASH short for non-alcoholic steatohepatitis has been a magnet for biotech investors over the past few years. NASH designates the most severe form of non-alc… read more...
Viking Therapeutics Won't Live Up To The Hype
via: SeekingAlpha at 2018-11-26 05:00:00:000
NASH an introduction Fatty deposits and mild fibrosis in non-alcoholic fatty liver disease. Source NASH short for non-alcoholic steatohepatitis has been a magnet for biotech investors over the past few years. NASH designates the most severe form of non-alc… read more...
DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
via: Business Wire at 2018-11-23 10:30:00:000
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of t… read more...
DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
via: Business Wire at 2018-11-23 10:30:00:000
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of t… read more...
DEADLINE MONDAY: The Schall Law Firm Announces it is Investigating Claims Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
via: Business Wire at 2018-11-23 10:30:00:000
The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of t… read more...
CURRENT SHAREHOLDERS: Zamansky LLC Investigates Alnylam Pharmaceuticals (ALNY) for Potential Breaches of Fiduciary Duties
via: Business Wire at 2018-11-21 16:35:00:000
Zamansky LLC announces that it is investigating Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NasdaqGS: ALNY) for potential breaches of fiduciary duties by its senior officers and board of directors. If you are a shareholder of Alnylam who still hold… read more...
CURRENT SHAREHOLDERS: Zamansky LLC Investigates Alnylam Pharmaceuticals (ALNY) for Potential Breaches of Fiduciary Duties
via: Business Wire at 2018-11-21 16:35:00:000
Zamansky LLC announces that it is investigating Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NasdaqGS: ALNY) for potential breaches of fiduciary duties by its senior officers and board of directors. If you are a shareholder of Alnylam who still hold… read more...
Alnylam to Webcast Presentations at Upcoming Investor Conferences
via: Business Wire at 2018-11-21 08:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 30 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 10:00 am ET at the Lo… read more...
Alnylam to Webcast Presentations at Upcoming Investor Conferences
via: Business Wire at 2018-11-21 08:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 30 th Annual Piper Jaffray Healthcare Conference on Wednesday, November 28, 2018 at 10:00 am ET at the Lo… read more...
A Sluggish Start With Onpattro Is Not What Alnylam Shareholders Needed
via: SeekingAlpha at 2018-11-20 05:21:30:000
Theres not much any company can do about a bad tape, but Alnylam ( ALNY ) has seen sentiment sour pretty sharply since late 2017 despite the approval and launch of its first drug Onpattro. Between worries about greater competition (moreso from Pfizer ( PFE ) than Ionis ( IONS )/ … read more...
INVESTOR REMINDER: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.
via: Business Wire at 2018-11-19 13:12:00:000
The law firm of Kessler Topaz Meltzer & Check, LLP reminds Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) (Alnylam) investors that a securities fraud class action lawsuit has been filed on behalf of purchasers of Alnylam securities between February 15, 2018 and September … read more...
Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important November 26 Deadline in Class Action - ALNY
via: PR Newswire at 2018-11-15 16:56:00:000
NEW YORK , Nov. 15, 2018 /PRNewswire/ --Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018 , inclusive (the "Class Period") of the important Nov… read more...
Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important November 26 Deadline in Class Action - ALNY
via: PR Newswire at 2018-11-15 16:56:00:000
NEW YORK , Nov. 15, 2018 /PRNewswire/ --Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018 , inclusive (the "Class Period") of the important Nov… read more...
Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important November 26 Deadline in Class Action - ALNY
via: PR Newswire at 2018-11-15 16:56:00:000
NEW YORK , Nov. 15, 2018 /PRNewswire/ --Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018 , inclusive (the "Class Period") of the important Nov… read more...
Biotechs getting slammed again, XBI down almost 4%
via: SeekingAlpha at 2018-11-12 11:45:16:000
In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...
Biotechs getting slammed again, XBI down almost 4%
via: SeekingAlpha at 2018-11-12 11:45:16:000
In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...
Biotechs getting slammed again, XBI down almost 4%
via: SeekingAlpha at 2018-11-12 11:45:16:000
In an all-too-frequent narrative, biotechs are getting roughed up yet again. The SPDR S&P Biotech ETF ( XBI -3.5% ) is in the red, albeit on below-average volume. The ETF has lost ~22% of its value in a little over two months. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, In… read more...
Alnylam's givosiran shows durable effect in hepatic porphyria study
via: SeekingAlpha at 2018-11-09 13:19:22:000
At data cutoff, the mean time on treatment was 13.6 months. Monthly dosing produced annualized attack rate (AAR) by 93% and annualized hemin use by 94% (hemin for injection, branded as Panhematin by Recordati Rare Diseases, works by lowering the production of certain enzymes in the body th… read more...
Alnylam's givosiran shows durable effect in hepatic porphyria study
via: SeekingAlpha at 2018-11-09 13:19:22:000
At data cutoff, the mean time on treatment was 13.6 months. Monthly dosing produced annualized attack rate (AAR) by 93% and annualized hemin use by 94% (hemin for injection, branded as Panhematin by Recordati Rare Diseases, works by lowering the production of certain enzymes in the body th… read more...
Alnylam's givosiran shows durable effect in hepatic porphyria study
via: SeekingAlpha at 2018-11-09 13:19:22:000
At data cutoff, the mean time on treatment was 13.6 months. Monthly dosing produced annualized attack rate (AAR) by 93% and annualized hemin use by 94% (hemin for injection, branded as Panhematin by Recordati Rare Diseases, works by lowering the production of certain enzymes in the body th… read more...
Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
via: Business Wire at 2018-11-09 08:00:00:000
Givosiran Demonstrated Sustained Clinical Activity, with an Over 90 Percent Decrease in Mean Annualized Porphyria Attack Rate, Relative to Baseline Safety Profile Encouraging with up to 25 Months of Treatment Alnylam Pharmaceuticals, Inc. 
… read more...
Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
via: Business Wire at 2018-11-09 08:00:00:000
Givosiran Demonstrated Sustained Clinical Activity, with an Over 90 Percent Decrease in Mean Annualized Porphyria Attack Rate, Relative to Baseline Safety Profile Encouraging with up to 25 Months of Treatment Alnylam Pharmaceuticals, Inc. 
… read more...
Alnylam Presents Updated Phase 1/2 Open-Label Extension (OLE) Results for Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria
via: Business Wire at 2018-11-09 08:00:00:000
Givosiran Demonstrated Sustained Clinical Activity, with an Over 90 Percent Decrease in Mean Annualized Porphyria Attack Rate, Relative to Baseline Safety Profile Encouraging with up to 25 Months of Treatment Alnylam Pharmaceuticals, Inc. 
… read more...
Alnylam Pharmaceuticals (ALNY) Q3 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-11-07 20:49:36:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q3 2018 Earnings Call November 07, 2018 8:30 am ET Executives Christine Regan Lindenboom - Alnylam Pharmaceuticals, Inc. John M. Maraganore - Alnylam Pharmaceuticals, Inc. Akshay K. Vaishnaw - Alnylam Pharmaceuticals, Inc. Barry E. Greene - … read more...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Alnylam Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - ALNY
via: PR Newswire at 2018-11-07 17:51:00:000
NEW YORK , Nov. 7, 2018 /PRNewswire/ --Pomerantz LLP announces that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY) and certain of its officers. The class action, filed in United States Distr… read more...
Alnylam Pharmaceuticals, Inc. 2018 Q3 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-11-07 10:18:30:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2018 Q3 earnings Read more … read more...
Alnylam Pharmaceuticals Q3 revenues down 88%
via: SeekingAlpha at 2018-11-07 08:41:26:000
Alnylam Pharmaceuticals ( ALNY ) Q3 results : Revenues: $2.1M (-87.7%). More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...
Alnylam Pharmaceuticals beats by $0.42, misses on revenue
via: SeekingAlpha at 2018-11-07 08:01:45:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q3 Non-GAAP EPS of -$1.56 beats by $0.42 ; GAAP EPS of -$2.43 misses by $0.45 . More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Alnylam Pharmaceuticals Reports Third Quarter 2018 Financial Results and Highlights Recent Period Activity
via: Business Wire at 2018-11-07 08:00:00:000
Obtained FDA and EMA Approvals of ONPATTRO (patisiran) the First-Ever RNAi Therapeutic and Launched in U.S. and EU Received 125 U.S. Patient Start Forms in First Seven Weeks of ONPATTRO Launch Reported Positive… read more...
Notable earnings before Wednesday's open
via: SeekingAlpha at 2018-11-06 17:30:01:000
ALNY , AMRX , ANDX , ASC , AVA , CARS , CDK , CLNY , CNDT , CNHI , COTY , CRL , CSTE , DF , DISH , DLPH , ENBL , FOXA , GEO , GIB , GRPN , HUM , HZNP , KELYA , KORS , MDP , MGLN , MIDD , MNTA , NSIT , ODP , PFGC , RCM , RDWR , ROK , SBGI , SMG , SMI , … read more...
Alnylam to Webcast Presentations at Upcoming Investor Conferences
via: Business Wire at 2018-11-06 16:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Stifel 2018 Healthcare Conference on Wednesday, November 14, 2018 at 10:15 am ET at the Lotte New York Pal… read more...
It's Time To Buy Microsoft - Cramer's Lightning Round (11/2/18)
via: SeekingAlpha at 2018-11-05 06:37:07:000
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Friday, November 2 . Bullish Calls Microsoft (MSFT): They reported a good quarter and the stock went down due to a selloff in tech. It's time to buy. ResMed (RMD): CEO Mark Farrell is doing a good job… read more...
Cramer's lightning round: It's time to buy the stock of Microsoft
via: CNBC at 2018-11-02 18:47:00:000
No summary available. read more...
Cramer's lightning round: It's time to buy the stock of Microsoft
via: CNBC at 2018-11-02 18:47:00:000
No summary available. read more...
Cramer's lightning round: It's time to buy the stock of Microsoft
via: CNBC at 2018-11-02 18:47:00:000
No summary available. read more...
Alnylam to Webcast Conference Call Discussing Third Quarter 2018 Financial Results
via: Business Wire at 2018-10-30 16:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2018 on Wednesday, November 7, 2018, before the U.S. financial markets open. Management will provide an … read more...
Alnylam to Webcast Conference Call Discussing Third Quarter 2018 Financial Results
via: Business Wire at 2018-10-30 16:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2018 on Wednesday, November 7, 2018, before the U.S. financial markets open. Management will provide an … read more...
Alnylam to Webcast Conference Call Discussing Third Quarter 2018 Financial Results
via: Business Wire at 2018-10-30 16:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2018 on Wednesday, November 7, 2018, before the U.S. financial markets open. Management will provide an … read more...
Lifshitz & Miller LLP Announces Investigation of Alnylam Pharmaceuticals, Inc., Campbell Soup Company, Fanhua Inc., Hasbro, Inc., OPKO Health, Inc., Pretium Resources, Inc., Rowan Companies PLC and SodaStream International Ltd.
via: PR Newswire at 2018-10-30 15:21:00:000
NEW YORK , Oct. 30, 2018 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (ALNY) Lifshitz & Miller announces investigation into possible securities laws violations in connection with FDA reviewers having concerns of a "potential platform safety risk" with the ONPATTRO trials… read more...
Lifshitz & Miller LLP Announces Investigation of Alnylam Pharmaceuticals, Inc., Campbell Soup Company, Fanhua Inc., Hasbro, Inc., OPKO Health, Inc., Pretium Resources, Inc., Rowan Companies PLC and SodaStream International Ltd.
via: PR Newswire at 2018-10-30 15:21:00:000
NEW YORK , Oct. 30, 2018 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (ALNY) Lifshitz & Miller announces investigation into possible securities laws violations in connection with FDA reviewers having concerns of a "potential platform safety risk" with the ONPATTRO trials… read more...
Lifshitz & Miller LLP Announces Investigation of Alnylam Pharmaceuticals, Inc., Campbell Soup Company, Fanhua Inc., Hasbro, Inc., OPKO Health, Inc., Pretium Resources, Inc., Rowan Companies PLC and SodaStream International Ltd.
via: PR Newswire at 2018-10-30 15:21:00:000
NEW YORK , Oct. 30, 2018 /PRNewswire/ -- Alnylam Pharmaceuticals, Inc. (ALNY) Lifshitz & Miller announces investigation into possible securities laws violations in connection with FDA reviewers having concerns of a "potential platform safety risk" with the ONPATTRO trials… read more...
Dicerna Pharmaceuticals Keeps The Deals Rolling In On The Promise Of Its Groundbreaking GalXC RNAi Technology
via: SeekingAlpha at 2018-10-30 09:54:50:000
Recently, Dicerna Pharmaceuticals ( DRNA ) announced a partnership with Eli Lilly ( LLY ) which amounts to an upfront payment and an equity stake . This is just one of the most recent validations of Dicerna's GalXC technology. Just this past week, Dicerna garnered another deal with Ale… read more...
Dicerna Pharmaceuticals Keeps The Deals Rolling In On The Promise Of Its Groundbreaking GalXC RNAi Technology
via: SeekingAlpha at 2018-10-30 09:54:50:000
Recently, Dicerna Pharmaceuticals ( DRNA ) announced a partnership with Eli Lilly ( LLY ) which amounts to an upfront payment and an equity stake . This is just one of the most recent validations of Dicerna's GalXC technology. Just this past week, Dicerna garnered another deal with Ale… read more...
Dicerna Pharmaceuticals Keeps The Deals Rolling In On The Promise Of Its Groundbreaking GalXC RNAi Technology
via: SeekingAlpha at 2018-10-30 09:54:50:000
Recently, Dicerna Pharmaceuticals ( DRNA ) announced a partnership with Eli Lilly ( LLY ) which amounts to an upfront payment and an equity stake . This is just one of the most recent validations of Dicerna's GalXC technology. Just this past week, Dicerna garnered another deal with Ale… read more...
Invitae expands work with Alnylam Pharmaceuticals to provide access to genetic testing for primary hyperoxaluria
via: PR Newswire at 2018-10-29 07:30:00:000
SAN FRANCISCO , Oct. 29, 2018 /PRNewswire/ -- Invitae Corporation (NYSE: NVTA), one of the fastest growing genetics companies, announced today it has expanded its partnership with Alnylam Pharmaceuticals , the leading RNAi therapeutics company, to provide genetic testing at no cos… read more...
Alnylam to offer free genetic testing/counseling for potential candidates in lumasiran studies
via: SeekingAlpha at 2018-10-25 13:56:26:000
Alnylam Pharmaceuticals ( ALNY +6.4% ) has expanded it Alnylam Act program to include free-of-charge third-party genetic testing and counseling for adults and children who may have AGXT mutations associated with primary hyperoxaluria type 1 (PH1). Identified patients may be suitable cand… read more...
Alnylam to offer free genetic testing/counseling for potential candidates in lumasiran studies
via: SeekingAlpha at 2018-10-25 13:56:26:000
Alnylam Pharmaceuticals ( ALNY +6.4% ) has expanded it Alnylam Act program to include free-of-charge third-party genetic testing and counseling for adults and children who may have AGXT mutations associated with primary hyperoxaluria type 1 (PH1). Identified patients may be suitable cand… read more...
Alnylam to offer free genetic testing/counseling for potential candidates in lumasiran studies
via: SeekingAlpha at 2018-10-25 13:56:26:000
Alnylam Pharmaceuticals ( ALNY +6.4% ) has expanded it Alnylam Act program to include free-of-charge third-party genetic testing and counseling for adults and children who may have AGXT mutations associated with primary hyperoxaluria type 1 (PH1). Identified patients may be suitable cand… read more...
Alnylam Expands Alnylam Act® Program to Improve Diagnosis of Primary Hyperoxaluria Type 1 (PH1) and Aligns with FDA on Trial Design for ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran
via: Business Wire at 2018-10-25 13:00:00:000
Alnylam Act to Include No-Charge Third-Party Genetic Testing and Counseling for Adults and Children at Risk for PH1 ILLUMINATE-B to Evaluate Safety and Efficacy of Lumasiran in PH1 Patients Under Six Years of Age Company Reports on New … read more...
Alnylam Expands Alnylam Act® Program to Improve Diagnosis of Primary Hyperoxaluria Type 1 (PH1) and Aligns with FDA on Trial Design for ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran
via: Business Wire at 2018-10-25 13:00:00:000
Alnylam Act to Include No-Charge Third-Party Genetic Testing and Counseling for Adults and Children at Risk for PH1 ILLUMINATE-B to Evaluate Safety and Efficacy of Lumasiran in PH1 Patients Under Six Years of Age Company Reports on New … read more...
Alnylam Expands Alnylam Act® Program to Improve Diagnosis of Primary Hyperoxaluria Type 1 (PH1) and Aligns with FDA on Trial Design for ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran
via: Business Wire at 2018-10-25 13:00:00:000
Alnylam Act to Include No-Charge Third-Party Genetic Testing and Counseling for Adults and Children at Risk for PH1 ILLUMINATE-B to Evaluate Safety and Efficacy of Lumasiran in PH1 Patients Under Six Years of Age Company Reports on New … read more...
ALNY NOTICE ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc., Important Deadline in Class Action - ALNY
via: PR Newswire at 2018-10-24 18:30:00:000
NEW YORK , Oct. 24, 2018 /PRNewswire/ --Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018 , … read more...
Alnylam Announces Advocacy for Impact Grants to Inspire Unique Solutions that Address Unmet Needs Affecting the Rare Disease Community
via: Business Wire at 2018-10-24 07:00:00:000
Alnylams Advocacy for Impact Grants Will Fund New Projects of Up to $50,000 to Patient Advocacy Groups that Impact the ATTR Amyloidosis, Acute Hepatic Porphyrias and/or Primary Hyperoxaluria Type 1 Communities Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY),… read more...
Biotechs set for down gap at open
via: SeekingAlpha at 2018-10-23 09:25:19:000
The SPDR S&P Biotech ETF (NYSEARCA: XBI ) is down 2% premarket on light volume, continuing its 2% slide yesterday. More news on: SPDR Biotech ETF, Amgen Inc., Biogen Inc., Healthcare stocks news, Stocks on the move, News on ETFs, Read more … read more...
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm
via: Business Wire at 2018-10-22 16:47:00:000
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ:ALNY) of the November 26, 2018 deadline to seek the role of lead plaintiff in a federal securities class actio… read more...
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Alnylam Pharmaceuticals, Inc. to Contact the Firm
via: Business Wire at 2018-10-19 14:57:00:000
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ:ALNY) of the November 26, 2018 deadline to seek the role of lead plaintiff in a federal securities class actio… read more...
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Alnylam Pharmaceuticals, Inc. to Contact the Firm
via: Business Wire at 2018-10-19 14:57:00:000
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ:ALNY) of the November 26, 2018 deadline to seek the role of lead plaintiff in a federal securities class actio… read more...
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 in Alnylam Pharmaceuticals, Inc. to Contact the Firm
via: Business Wire at 2018-10-19 14:57:00:000
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ:ALNY) of the November 26, 2018 deadline to seek the role of lead plaintiff in a federal securities class actio… read more...
Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran
via: Business Wire at 2018-10-15 07:00:00:000
Topline Results on Primary Endpoint of Annualized Attack Rate Expected in Early 2019 Company Plans to Initiate a Rolling Submission of an NDA in 2018 with Addition of Full Clinical Results in Mid-2019 in Support of a Full Approval Alnylam Phar… read more...
Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran
via: Business Wire at 2018-10-15 07:00:00:000
Topline Results on Primary Endpoint of Annualized Attack Rate Expected in Early 2019 Company Plans to Initiate a Rolling Submission of an NDA in 2018 with Addition of Full Clinical Results in Mid-2019 in Support of a Full Approval Alnylam Phar… read more...
Alnylam Announces Plan to Initiate Rolling Submission of a New Drug Application and Pursue Full Approval for Givosiran
via: Business Wire at 2018-10-15 07:00:00:000
Topline Results on Primary Endpoint of Annualized Attack Rate Expected in Early 2019 Company Plans to Initiate a Rolling Submission of an NDA in 2018 with Addition of Full Clinical Results in Mid-2019 in Support of a Full Approval Alnylam Phar… read more...
Catalyst Biosciences: Rare Risk/Reward Opportunity
via: SeekingAlpha at 2018-10-14 22:32:37:000
General Overview of Pipeline Catalyst Biosciences ( CBIO ) is a clinical-stage biopharmaceutical company focused on developing hemostasis treatments. Since the company became public after a merger deal with Targacept, it is known that Catalyst has engineered three therapeutic candidates … read more...
Catalyst Biosciences: Rare Risk/Reward Opportunity
via: SeekingAlpha at 2018-10-14 22:32:37:000
General Overview of Pipeline Catalyst Biosciences ( CBIO ) is a clinical-stage biopharmaceutical company focused on developing hemostasis treatments. Since the company became public after a merger deal with Targacept, it is known that Catalyst has engineered three therapeutic candidates … read more...
Catalyst Biosciences: Rare Risk/Reward Opportunity
via: SeekingAlpha at 2018-10-14 22:32:37:000
General Overview of Pipeline Catalyst Biosciences ( CBIO ) is a clinical-stage biopharmaceutical company focused on developing hemostasis treatments. Since the company became public after a merger deal with Targacept, it is known that Catalyst has engineered three therapeutic candidates … read more...
Alnylam Appoints Dr. Margaret Hamburg to Board of Directors
via: Business Wire at 2018-10-10 07:00:00:000
Dr. Hamburg is Former FDA Commissioner and Internationally Recognized as a Distinguished Authority in Medicine, Regulatory Science and Public Health Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the appointment … read more...
Alnylam Appoints Dr. Margaret Hamburg to Board of Directors
via: Business Wire at 2018-10-10 07:00:00:000
Dr. Hamburg is Former FDA Commissioner and Internationally Recognized as a Distinguished Authority in Medicine, Regulatory Science and Public Health Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the appointment … read more...
Alnylam Appoints Dr. Margaret Hamburg to Board of Directors
via: Business Wire at 2018-10-10 07:00:00:000
Dr. Hamburg is Former FDA Commissioner and Internationally Recognized as a Distinguished Authority in Medicine, Regulatory Science and Public Health Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced the appointment … read more...
Arbutus Biopharma: The Good, The Bad, And The Ugly
via: SeekingAlpha at 2018-10-09 11:25:50:000
Introduction Arbutus Biopharma ( ABUS ) is one of the many biotech companies focused on the research and development of Hepatitis B therapeutics. What helps make the company stand out from the crowd is its diverse pipeline and financial situation. The company has made great strides in deve… read more...
Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against Alnylam Pharmaceuticals, Inc.
via: Business Wire at 2018-10-09 09:26:00:000
The law firm of Kessler Topaz Meltzer & Check, LLP reminds that an investor securities fraud class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) (Alnylam) on behalf of purchasers of Alnylam securities between February 15, 2018 and Se… read more...
Robbins Arroyo LLP: Alnylam Pharmaceuticals, Inc. (ALNY) Sued by Shareholders in Recently Filed Class Action
via: Business Wire at 2018-10-08 15:56:00:000
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) have filed a class action complaint against the company's officers and directors for alleged violations of the Securities Exchange Act of 1934 between February 15, 2018 … read more...
FDA nod for Akcea's intersen fails to lift shares, down 16%
via: SeekingAlpha at 2018-10-08 15:43:40:000
Ionis Pharmaceuticals ( IONS -8.5% ) and affiliate Akcea Therapeutics ( AKCA -15.7% ) slump on increased volume following FDA approval for TEGSEDI (inotersen) for hATTR. Normally, a bullish event but investors appear concerned about its ability to compete with Alnylam Pharmaceuticals' ( … read more...
Lilly Surges On Pipeline News: Analysis And Trading Thoughts
via: SeekingAlpha at 2018-10-08 14:49:36:000
Introduction Eli Lilly ( LLY ) has been on a roll, powered by some fast-growing young products, some resiliency of its older stalwarts, and a promising pipeline. See p. 12 of LLY's Q2 detailed earnings release for a list of sales and yoy growth rates for these drugs. The reason I have rent… read more...
ALNY LOSS NOTICE: Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important Deadline in Class Action - ALNY
via: Business Wire at 2018-10-06 15:00:00:000
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018, inclusive (the Class Period) of the important November 26, 2018 lead plaintiff deadline i… read more...
ALNY LOSS NOTICE: Rosen Law Firm Reminds Alnylam Pharmaceuticals, Inc. Investors of Important Deadline in Class Action - ALNY
via: Business Wire at 2018-10-06 15:00:00:000
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018, inclusive (the Class Period) of the important November 26, 2018 lead plaintiff deadline i… read more...
FDA OKs Akcea's inotersen for hATTR
via: SeekingAlpha at 2018-10-06 14:12:09:000
The FDA approves Akcea Therapeutics' (NASDAQ: AKCA ) TEGSEDI (inotersen) for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR). More news on: Akcea Therapeutics, Express Scripts, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news,… read more...
FDA OKs Akcea's inotersen for hATTR
via: SeekingAlpha at 2018-10-06 14:12:09:000
The FDA approves Akcea Therapeutics' (NASDAQ: AKCA ) TEGSEDI (inotersen) for the treatment of polyneuropathy in adults with hereditary transthyretin-mediated amyloidosis (hATTR). More news on: Akcea Therapeutics, Express Scripts, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news,… read more...
Alnylam reports positive results from Phase 1/2 study of lumasiran in patients with PH1
via: SeekingAlpha at 2018-10-04 07:42:12:000
Alnylam Pharmaceuticals(NASDAQ: ALNY ) reports updated positive results from its Phase 1/2 clinical study of lumasiran, an RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1 (PH1). More news on: Alnylam Pharmaceuticals, Inc., Healthcare s… read more...
Alnylam reports positive results from Phase 1/2 study of lumasiran in patients with PH1
via: SeekingAlpha at 2018-10-04 07:42:12:000
Alnylam Pharmaceuticals(NASDAQ: ALNY ) reports updated positive results from its Phase 1/2 clinical study of lumasiran, an RNAi therapeutic targeting glycolate oxidase for the treatment of primary hyperoxaluria type 1 (PH1). More news on: Alnylam Pharmaceuticals, Inc., Healthcare s… read more...
Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1
via: Business Wire at 2018-10-04 07:00:00:000
Lumasiran Treatment Resulted in 75 Percent Mean Maximal Reduction in Urinary Oxalate Relative to Baseline, with 100 Percent of Patients Achieving Levels of Urinary Oxalate Less Than 1.5 Times Upper Limit of Normal Lumasiran Shows Encouraging Safety Profile wi… read more...
Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1
via: Business Wire at 2018-10-04 07:00:00:000
Lumasiran Treatment Resulted in 75 Percent Mean Maximal Reduction in Urinary Oxalate Relative to Baseline, with 100 Percent of Patients Achieving Levels of Urinary Oxalate Less Than 1.5 Times Upper Limit of Normal Lumasiran Shows Encouraging Safety Profile wi… read more...
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Alnylam Pharmaceuticals, Inc. - ALNY
via: PR Newswire at 2018-10-03 14:30:00:000
RADNOR, Pa. , Oct. 3, 2018 /PRNewswire/ --The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) ("Alnylam") on behalf of purchasers of Alnylam securitie… read more...
Alnylam Submits Clinical Trial Authorization (CTA) Application for ALN-AAT02, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)
via: Business Wire at 2018-10-03 07:00:00:000
ALN-AAT02 is the First Investigational RNAi Therapeutic to Utilize Alnylams Enhanced Stabilization Chemistry Plus (ESC+) GalNAc-Conjugate Technology Company Expects to Initiate Phase 1/2 Study by Year-End 2018 Alnylam Pharmaceuticals, … read more...
Alnylam Launches ONPATTRO(TM) (patisiran), the First-Ever RNAi Therapeutic, in Germany
via: Business Wire at 2018-10-02 16:00:00:000
ONPATTRO Indicated for Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR Amyloidosis) in Adults with Stage 1 or Stage 2 Polyneuropathy Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics com… read more...
Alnylam Reports New Platform Innovations for RNAi Therapeutics at the Oligonucleotide Therapeutics Society 2018 Annual Meeting
via: Business Wire at 2018-10-02 14:50:00:000
Achieves Robust and Durable Target Gene Silencing with Central Nervous System Delivery of Novel siRNA Conjugates in Non-Human Primates Extends Progress on Extrahepatic Delivery with Ocular Disease Targets Alnylam Pharmaceuticals, Inc.  … read more...
NASH players under pressure following Liver Meeting abstract drop
via: SeekingAlpha at 2018-10-02 12:50:37:000
Biotechs developing treatments for nonalcoholic steatohepatitis (NASH) and other fatty liver diseases are seeing some action following the release of abstracts for November's Liver Meeting in San Francisco. More news on: NGM Biopharmaceuticals, Viking Therapeutics, Madrigal Pharmaceuticals… read more...
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
via: Business Wire at 2018-10-01 19:49:00:000
The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of the Securities… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-10-01 08:48:56:000
Neon Therapeutics (NASDAQ: NTGN ) initiated with Buy rating and $20 (134% upside) price target at Ladenburg Thalmann. More news on: Neon Therapeutics, Incyte Corporation, Intercept Pharmaceuticals, Healthcare stocks news, Stocks on the move, , Read more … read more...
The Medicines Company's late-stage inclisiran studies to continue as planned
via: SeekingAlpha at 2018-10-01 08:08:01:000
Based on the fourth planned IDMC review of three ongoing Phase 3 clinical trials, ORION-9, -10 and -11, evaluating The Medicines Company's (NASDAQ: MDCO ) inclisiran in patients with inherited high levels of cholesterol, the studies will continue as planned . Topline data should be availabl… read more...
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
via: Business Wire at 2018-09-28 11:34:00:000
The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of the Securities… read more...
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
via: Business Wire at 2018-09-28 11:34:00:000
The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of the Securities… read more...
IMPORTANT INVESTOR NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
via: Business Wire at 2018-09-28 11:34:00:000
The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) for violations of 10(b) and 20(a) of the Securities… read more...
Alnylam submits Onpattro marketing application in Japan
via: SeekingAlpha at 2018-09-28 07:20:04:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) has filed a marketing application in Japan seeking approval for ONPATTRO (patisiran sodium) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis, an Orphan Drug indication there. More news on: Alnylam Pharmaceuticals, Inc., He… read more...
Alnylam submits Onpattro marketing application in Japan
via: SeekingAlpha at 2018-09-28 07:20:04:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) has filed a marketing application in Japan seeking approval for ONPATTRO (patisiran sodium) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis, an Orphan Drug indication there. More news on: Alnylam Pharmaceuticals, Inc., He… read more...
Alnylam submits Onpattro marketing application in Japan
via: SeekingAlpha at 2018-09-28 07:20:04:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) has filed a marketing application in Japan seeking approval for ONPATTRO (patisiran sodium) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis, an Orphan Drug indication there. More news on: Alnylam Pharmaceuticals, Inc., He… read more...
Alnylam Announces Submission of New Drug Application in Japan for ONPATTRO(TM) (patisiran sodium) for Treatment of Hereditary ATTR Amyloidosis
via: Business Wire at 2018-09-28 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has submitted a New Drug Application (NDA) to Japans Pharmaceuticals and Medical Devices Agency (PMDA) for approval of patisiran for the treatment of hereditary transthyreti… read more...
Alnylam Announces Submission of New Drug Application in Japan for ONPATTRO(TM) (patisiran sodium) for Treatment of Hereditary ATTR Amyloidosis
via: Business Wire at 2018-09-28 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has submitted a New Drug Application (NDA) to Japans Pharmaceuticals and Medical Devices Agency (PMDA) for approval of patisiran for the treatment of hereditary transthyreti… read more...
Alnylam Announces Submission of New Drug Application in Japan for ONPATTRO(TM) (patisiran sodium) for Treatment of Hereditary ATTR Amyloidosis
via: Business Wire at 2018-09-28 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it has submitted a New Drug Application (NDA) to Japans Pharmaceuticals and Medical Devices Agency (PMDA) for approval of patisiran for the treatment of hereditary transthyreti… read more...
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Alnylam Pharmaceuticals, Inc. To Contact The Firm
via: PR Newswire at 2018-09-27 18:06:00:000
NEW YORK , Sept. 27, 2018 /PRNewswire/ --Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ:ALNY) of the November 26, 2018 deadline to seek the role of lead plaintiff in a federa… read more...
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Alnylam Pharmaceuticals, Inc. Investors (ALNY)
via: Business Wire at 2018-09-27 17:00:00:000
Glancy Prongay & Murray LLP (GPM) announces an investigation on behalf of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) investors concerning the Company and its officers possible violations of federal sec… read more...
Alnylam Pharmaceuticals Could Use Some Straightforward Good News
via: SeekingAlpha at 2018-09-27 16:13:30:000
Alynlam Pharmaceuticals ( ALNY ) could really use some straightforward, clean, good news right now, as several of the companys recent positive events have been yes but situations. Todays update on givosiran in acute hepatic porphyria is a case in a po… read more...
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Alnylam Pharmaceuticals, Inc. (ALNY) and Lead Plaintiff Deadline - November 26, 2018
via: PR Newswire at 2018-09-27 15:02:00:000
NEW YORK , Sept. 27, 2018 /PRNewswire/ --Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Alnylam Pharmaceuticals, Inc.("Alnylam" or the "Company") (NASDAQ: ALNY) and certain of its officers, o… read more...
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Alnylam Pharmaceuticals, Inc. Investors (ALNY)
via: Business Wire at 2018-09-27 14:44:00:000
Law Offices of Howard G. Smithannounces an investigation on behalf of Alnylam Pharmaceuticals, Inc. (Alnylam or the Company) (NASDAQ: ALNY ) investors concerning the Company and its officers possible violations of federal securities laws. Th… read more...
ALNYLAM CLASS ACTION LAWSUIT: BERNSTEIN LIEBHARD LLP ANNOUNCES THAT A SECURITIES CLASS ACTION LAWSUIT HAS BEEN FILED AGAINST ALNYLAM PHARMACEUTICALS, INC. - ALNY
via: PR Newswire at 2018-09-27 10:38:00:000
NEW YORK , Sept. 27, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, anationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of those who purchased or acquired the securities of Alnylam Pharmaceuticals, Inc. ("Alnylam" o… read more...
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Alnylam Pharmaceuticals, Inc. - ALNY
via: Business Wire at 2018-09-27 10:35:00:000
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) from February 15, 2018 through September 12, 2018, inclusive (the Class Period). The law… read more...
Alnylam's givosiran shows positive effect in late-stage AHP study; U.S. marketing application planned; shares ahead 2% premarket
via: SeekingAlpha at 2018-09-27 07:41:46:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) is up 2% premarket on light volume on the heels of its announcement of positive results from a Phase 3 clinical trial, ENVISION , evaluating givosiran in patients with acute hepatic porphyria (AHP), an inherited disorder affecting the … read more...
Alnylam Announces Positive Topline Results from Interim Analysis of ENVISION Phase 3 Study of Givosiran in Patients with Acute Hepatic Porphyria
via: Business Wire at 2018-09-27 07:00:00:000
Givosiran Treatment Resulted in Significant Reduction of Urinary Aminolevulinic Acid (ALA), a Disease Biomarker Reasonably Likely to Predict Clinical Benefit Company Plans to Discuss Results with FDA Regarding a Potential NDA Filing at or Around Year-End in S… read more...
Alnylam to Webcast Presentation at the 2018 Cantor Global Healthcare Conference
via: Business Wire at 2018-09-26 08:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 2018 Cantor Global Healthcare Conference on Wednesday, October 3, 2018 at 9:45 am ET at the InterContinental New York Barclay Hotel in… read more...
Making Sense Of Alnylam's Valuation
via: SeekingAlpha at 2018-09-24 02:24:27:000
Company Overview Alnylam ( ALNY ) is a biopharma company developing small molecules based on RNA interference (RNAi), which is a naturally occurring biological pathway for sequence-specific silencing and regulation of gene expression. RNAi therapeutics include silencing messenger RNA that … read more...
Making Sense Of Alnylam's Valuation
via: SeekingAlpha at 2018-09-24 02:24:27:000
Company Overview Alnylam ( ALNY ) is a biopharma company developing small molecules based on RNA interference (RNAi), which is a naturally occurring biological pathway for sequence-specific silencing and regulation of gene expression. RNAi therapeutics include silencing messenger RNA that … read more...
ALNYLAM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alnylam Pharmaceuticals, Inc. To Contact The Firm
via: PR Newswire at 2018-09-20 17:21:00:000
NEW YORK , Sept. 20, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities claims against Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). If you invested in Alnylam stock or … read more...
ALNYLAM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alnylam Pharmaceuticals, Inc. To Contact The Firm
via: PR Newswire at 2018-09-20 17:21:00:000
NEW YORK , Sept. 20, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities claims against Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). If you invested in Alnylam stock or … read more...
ALNYLAM INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Alnylam Pharmaceuticals, Inc. To Contact The Firm
via: PR Newswire at 2018-09-20 17:21:00:000
NEW YORK , Sept. 20, 2018 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities claims against Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). If you invested in Alnylam stock or … read more...
Your Daily Pharma Scoop: Alnylam Regains, Karyopharm Positive, Teva Approved
via: SeekingAlpha at 2018-09-18 10:45:37:000
Results from an exploratory Phase 3 trial of Alnylam Pharmaceuticalss ( ALNY ) Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published in the journal Circulation . Left… read more...
Your Daily Pharma Scoop: Alnylam Regains, Karyopharm Positive, Teva Approved
via: SeekingAlpha at 2018-09-18 10:45:37:000
Results from an exploratory Phase 3 trial of Alnylam Pharmaceuticalss ( ALNY ) Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published in the journal Circulation . Left… read more...
Alnylam announces publication of data showing effect of patisiran on cardiac disease in hATTR
via: SeekingAlpha at 2018-09-14 08:01:34:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that results from exploratory cardiac assessments in the Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published online in the j… read more...
Alnylam announces publication of data showing effect of patisiran on cardiac disease in hATTR
via: SeekingAlpha at 2018-09-14 08:01:34:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that results from exploratory cardiac assessments in the Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published online in the j… read more...
Alnylam announces publication of data showing effect of patisiran on cardiac disease in hATTR
via: SeekingAlpha at 2018-09-14 08:01:34:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that results from exploratory cardiac assessments in the Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published online in the j… read more...
Alnylam announces publication of data showing effect of patisiran on cardiac disease in hATTR
via: SeekingAlpha at 2018-09-14 08:01:34:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) announces that results from exploratory cardiac assessments in the Phase 3 APOLLO study evaluating ONPATTRO (patisiran) for the treatment of polyneuropathy in hereditary transthyretin-mediated (hATTR) amyloidosis were just published online in the j… read more...
Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran
via: Business Wire at 2018-09-14 06:00:00:000
Published Data From the APOLLO Study Show That Patisiran Improved Markers of Cardiomyopathy in Patients with Hereditary ATTR Amyloidosis with Polyneuropathy In Exploratory Post-Hoc Analysis, Reduction of All-Cause Mortality and Hospitalization Was Observed in… read more...
Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran
via: Business Wire at 2018-09-14 06:00:00:000
Published Data From the APOLLO Study Show That Patisiran Improved Markers of Cardiomyopathy in Patients with Hereditary ATTR Amyloidosis with Polyneuropathy In Exploratory Post-Hoc Analysis, Reduction of All-Cause Mortality and Hospitalization Was Observed in… read more...
Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran
via: Business Wire at 2018-09-14 06:00:00:000
Published Data From the APOLLO Study Show That Patisiran Improved Markers of Cardiomyopathy in Patients with Hereditary ATTR Amyloidosis with Polyneuropathy In Exploratory Post-Hoc Analysis, Reduction of All-Cause Mortality and Hospitalization Was Observed in… read more...
Alnylam Announces Publication in Circulation of Exploratory Cardiac Endpoint Data from APOLLO Phase 3 Study of Patisiran
via: Business Wire at 2018-09-14 06:00:00:000
Published Data From the APOLLO Study Show That Patisiran Improved Markers of Cardiomyopathy in Patients with Hereditary ATTR Amyloidosis with Polyneuropathy In Exploratory Post-Hoc Analysis, Reduction of All-Cause Mortality and Hospitalization Was Observed in… read more...
Alnylam Investigation: Bernstein Liebhard LLP Announces Investigation Of Alnylam Pharmaceuticals, Inc. - ALNY
via: PR Newswire at 2018-09-13 15:38:00:000
NEW YORK , Sept. 13, 2018 /PRNewswire/ -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY) resulting from alleg… read more...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alnylam Pharmaceuticals, Inc. - ALNY
via: PR Newswire at 2018-09-12 17:42:00:000
NEW YORK , Sept. 12, 2018 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com … read more...
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Alnylam Pharmaceuticals, Inc. (ALNY)
via: PR Newswire at 2018-09-12 14:14:00:000
NEW YORK , Sept. 12, 2018 /PRNewswire/ -- Attorney Advertising --Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Alnylam Pharmaceuticals, Inc.("Alnylam" or the "Company") (NASDAQ: ALNY). Such investors are encouraged to obtai… read more...
Alnylam Pharmaceuticals (ALNY) ONPATTRO And Investigational ALN-TTRsc02 For The Treatment Of ATTR Amyloidosis - Slideshow
via: SeekingAlpha at 2018-09-11 13:47:25:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Alnylam: Analysts See A Comet On The Rise
via: SeekingAlpha at 2018-09-06 15:01:50:000
Biopharma company Alnylam Pharmaceuticals (NASDAQ: ALNY ) has built a brand on its innovative RNAi therapeutics. ALNYs focus: developing a pipeline of drugs designed to help transform lives of patients with rare diseases. These are the patients facing either limited treatment options- … read more...
Alnylam: Analysts See A Comet On The Rise
via: SeekingAlpha at 2018-09-06 15:01:50:000
Biopharma company Alnylam Pharmaceuticals (NASDAQ: ALNY ) has built a brand on its innovative RNAi therapeutics. ALNYs focus: developing a pipeline of drugs designed to help transform lives of patients with rare diseases. These are the patients facing either limited treatment options- … read more...
Alnylam: Analysts See A Comet On The Rise
via: SeekingAlpha at 2018-09-06 15:01:50:000
Biopharma company Alnylam Pharmaceuticals (NASDAQ: ALNY ) has built a brand on its innovative RNAi therapeutics. ALNYs focus: developing a pipeline of drugs designed to help transform lives of patients with rare diseases. These are the patients facing either limited treatment options- … read more...
A Second Look At Inotersen's Approval Potential
via: SeekingAlpha at 2018-09-04 17:46:38:000
Editor's note: Seeking Alpha is proud to welcome Chris Stang as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Last week, Io… read more...
A Second Look At Inotersen's Approval Potential
via: SeekingAlpha at 2018-09-04 17:46:38:000
Editor's note: Seeking Alpha is proud to welcome Chris Stang as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Last week, Io… read more...
Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval
via: SeekingAlpha at 2018-09-01 05:42:38:000
Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516… read more...
Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval
via: SeekingAlpha at 2018-09-01 05:42:38:000
Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516… read more...
Your Daily Pharma Scoop: Pfizer Abandons Drug, Adverum's IND, Merck's HIV Approval
via: SeekingAlpha at 2018-09-01 05:42:38:000
Stocks in News: PFE, ADVM Pfizer bails on DMD candidate domagrozumab Discussion: Pfizer ( PFE ) announced termination of its domagrozumab (PF-06252616) indicated for the treatment of Duchenne muscular dystrophy ((DMD)). The decision followed a disappointing Phase 2 study (B516… read more...
Over-Extrapolation Of Pfizer Cardiomyopathy Data Creates Buying Opportunity For Eidos
via: SeekingAlpha at 2018-08-30 10:00:06:000
Pfizer ( PFE ) just announced the results for their Phase 3 ATTR-CM trial at the ESC Congress 2018. Pfizer reported a 30% reduction in the risk of all-cause mortality and a 32% reduction in the rate of CV-related hospitalization with tafamidis compared with placebo. The data can be found in … read more...
Over-Extrapolation Of Pfizer Cardiomyopathy Data Creates Buying Opportunity For Eidos
via: SeekingAlpha at 2018-08-30 10:00:06:000
Pfizer ( PFE ) just announced the results for their Phase 3 ATTR-CM trial at the ESC Congress 2018. Pfizer reported a 30% reduction in the risk of all-cause mortality and a 32% reduction in the rate of CV-related hospitalization with tafamidis compared with placebo. The data can be found in … read more...
Alnylam's patisiran OK'd in Europe for hATTR amyoidosis
via: SeekingAlpha at 2018-08-30 07:42:54:000
The European Commission approves Alnylam Pharmaceuticals' (NASDAQ: ALNY ) ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stager 1 or stage 2 polyneuropathy. More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals,… read more...
Alnylam's patisiran OK'd in Europe for hATTR amyoidosis
via: SeekingAlpha at 2018-08-30 07:42:54:000
The European Commission approves Alnylam Pharmaceuticals' (NASDAQ: ALNY ) ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated (hATTR) amyloidosis in adults with stager 1 or stage 2 polyneuropathy. More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals,… read more...
FDA OK's Bayer's Jivi for hemophilia A
via: SeekingAlpha at 2018-08-30 07:37:13:000
The FDA approves Bayer's ( OTCPK:BAYRY ) Jivi (antihemophilic factor [recombinant] PEGylated-aucl) for the routine prophylactic treatment of hemophilia A in previously treated patients at least 12 years old. More news on: Bayer A.G. ADR, Catalyst Biosciences, Inc., Sangamo Therapeutics, … read more...
FDA OK's Bayer's Jivi for hemophilia A
via: SeekingAlpha at 2018-08-30 07:37:13:000
The FDA approves Bayer's ( OTCPK:BAYRY ) Jivi (antihemophilic factor [recombinant] PEGylated-aucl) for the routine prophylactic treatment of hemophilia A in previously treated patients at least 12 years old. More news on: Bayer A.G. ADR, Catalyst Biosciences, Inc., Sangamo Therapeutics, … read more...
Alnylam Receives Approval of ONPATTRO(TM) (patisiran) in Europe
via: Business Wire at 2018-08-30 07:00:00:000
ONPATTRO Indicated for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in Adults with Stage 1 or Stage 2 Polyneuropathy First-Ever RNAi Therapeutic Approved in the European Union (EU) Alnylam Pharmace… read more...
Alnylam Receives Approval of ONPATTRO(TM) (patisiran) in Europe
via: Business Wire at 2018-08-30 07:00:00:000
ONPATTRO Indicated for the Treatment of Hereditary Transthyretin-Mediated (hATTR) Amyloidosis (hATTR amyloidosis) in Adults with Stage 1 or Stage 2 Polyneuropathy First-Ever RNAi Therapeutic Approved in the European Union (EU) Alnylam Pharmace… read more...
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
via: Business Wire at 2018-08-29 09:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 2018 Wells Fargo Securities Healthcare Conference on Wednesday, September 5, 2018 at 10:15 am ET at the We… read more...
Pfizer's Tafamidis Will Be Standard Of Care For A Not-So-Rare Disease
via: SeekingAlpha at 2018-08-28 14:23:45:000
Novel drugs that are shown to improve survival in patients with a lethal condition quickly become standard of care for that condition. The ATTR-ACT Study sponsored by Pfizer ( PFE ) and published in Monday's issue of NEJM includes survival curves for TTR (transthyretin-related) amyloid heart… read more...
Pfizer Achieves Success In Rare Heart Disease Study
via: SeekingAlpha at 2018-08-28 13:34:45:000
Recently, Pfizer ( PFE ) released final results from its phase 3 study treating patients with a rare heart disease known as Transthyretin cardiomyopathy (TTR-CM). The results were released at a presentation at the ESC Congress 2018. The results were positive, and now the company can expl… read more...
Approval, Labeling, Pricing, And Competitor Data All Give Alnylam Pharmaceuticals A Wild Ride
via: SeekingAlpha at 2018-08-28 12:21:20:000
Its been an interesting period of time to be an Alnylam ( ALNY ) shareholder, as the company got its first FDA approval (Onpattro), but with a narrower label than hoped and a somewhat confusing price structure. On top of that, a key potential competitor that wasnt even seen a… read more...
Midday Gainers / Losers (08/27/2018)
via: SeekingAlpha at 2018-08-27 12:48:12:000
Gainers: TIS +37% . HMNY +37% . CRON +21% . TLRY +20% . ALNY +17% . JMEI +17% . CTXR +18% . LAC +15% . KONE +14% . LEVB +13% . More news on: Orchids Paper Products Company, Helios and Matheson Analytics, Inc., Cronos Group, Inc., Stocks on the move, , … read more...
Money flow stays positive in biotechs, XBI up 6% since last week
via: SeekingAlpha at 2018-08-27 11:39:49:000
Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped 6% since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the … read more...
Sell-siders bullish on Pfizer tafamidis after release of positive data
via: SeekingAlpha at 2018-08-27 10:22:07:000
Sell-side analysts weigh in on Pfizer's ( PFE -1.9% ) Vyndaqel (tafamidis) after the company released late-stage data in patients with wild-type or variant (hereditary) transthyretin amyloid cardiomyopathy. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Eidos Therapeutics, Hea… read more...
Alnylam and Ionis up on lower perceived threat from Pfizer's tafamidis in ATTR
via: SeekingAlpha at 2018-08-27 09:44:15:000
Alnylam Pharmaceuticals ( ALNY +4.6% ) is up in early trade on the heels of Pfizer's ( PFE -0.9% ) announced late-stage data on tafamidis in transthyretin amyloid cardiomyopathy. More news on: Alnylam Pharmaceuticals, Inc., Pfizer Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks ne… read more...
Alnylam: Fully Priced, But A Future Star
via: SeekingAlpha at 2018-08-21 13:06:20:000
Investors often talk of getting in on the next big thing. But it is hard to know when a small thing will become big. I believe Alnylam ( ALNY ), which specializes in RNA based therapies, is part of a small number of biotechnology companies that will be part of a very big therapeutic space over… read more...
Alnylam: Fully Priced, But A Future Star
via: SeekingAlpha at 2018-08-21 13:06:20:000
Investors often talk of getting in on the next big thing. But it is hard to know when a small thing will become big. I believe Alnylam ( ALNY ), which specializes in RNA based therapies, is part of a small number of biotechnology companies that will be part of a very big therapeutic space over… read more...
Alnylam: Fully Priced, But A Future Star
via: SeekingAlpha at 2018-08-21 13:06:20:000
Investors often talk of getting in on the next big thing. But it is hard to know when a small thing will become big. I believe Alnylam ( ALNY ), which specializes in RNA based therapies, is part of a small number of biotechnology companies that will be part of a very big therapeutic space over… read more...
Alnylam competes enrollment in late-stage study of givosiran in AHP
via: SeekingAlpha at 2018-08-21 07:29:04:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) has completed enrollment of 94 subjects in its Phase 3 ENVISION study evaluating givosiran in patients with acute hepatic porphyrias (AHP), an inherited family of liver disorders caused by an enzyme deficiency characterized by abdominal pain and … read more...
Alnylam competes enrollment in late-stage study of givosiran in AHP
via: SeekingAlpha at 2018-08-21 07:29:04:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) has completed enrollment of 94 subjects in its Phase 3 ENVISION study evaluating givosiran in patients with acute hepatic porphyrias (AHP), an inherited family of liver disorders caused by an enzyme deficiency characterized by abdominal pain and … read more...
Alnylam competes enrollment in late-stage study of givosiran in AHP
via: SeekingAlpha at 2018-08-21 07:29:04:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ) has completed enrollment of 94 subjects in its Phase 3 ENVISION study evaluating givosiran in patients with acute hepatic porphyrias (AHP), an inherited family of liver disorders caused by an enzyme deficiency characterized by abdominal pain and … read more...
Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
via: Business Wire at 2018-08-21 07:00:00:000
Enrollment Completed Ahead of Schedule, Eight Months After First Patient Randomized Company Remains on Track to Report Interim Analysis Data by the End of September and Full Study Data in Early 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq:… read more...
Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
via: Business Wire at 2018-08-21 07:00:00:000
Enrollment Completed Ahead of Schedule, Eight Months After First Patient Randomized Company Remains on Track to Report Interim Analysis Data by the End of September and Full Study Data in Early 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq:… read more...
Alnylam Completes Enrollment in ENVISION Phase 3 Study of Givosiran, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyrias (AHPs)
via: Business Wire at 2018-08-21 07:00:00:000
Enrollment Completed Ahead of Schedule, Eight Months After First Patient Randomized Company Remains on Track to Report Interim Analysis Data by the End of September and Full Study Data in Early 2019 Alnylam Pharmaceuticals, Inc. (Nasdaq:… read more...
The Battle For Best-In-Class In ATTR Has Begun
via: SeekingAlpha at 2018-08-16 11:52:57:000
With Alnylam (NASDAQ: ALNY ) securing FDA approval for Onpattro on Friday, August 10 th , 2018, the battle for "best-in-class" in transthyretin amyloidosis (ATTR) has officially begun. This approval gives Alnylam the early lead. Other competitors in the clinic include Ionis (NASDAQ:… read more...
The Battle For Best-In-Class In ATTR Has Begun
via: SeekingAlpha at 2018-08-16 11:52:57:000
With Alnylam (NASDAQ: ALNY ) securing FDA approval for Onpattro on Friday, August 10 th , 2018, the battle for "best-in-class" in transthyretin amyloidosis (ATTR) has officially begun. This approval gives Alnylam the early lead. Other competitors in the clinic include Ionis (NASDAQ:… read more...
The Battle For Best-In-Class In ATTR Has Begun
via: SeekingAlpha at 2018-08-16 11:52:57:000
With Alnylam (NASDAQ: ALNY ) securing FDA approval for Onpattro on Friday, August 10 th , 2018, the battle for "best-in-class" in transthyretin amyloidosis (ATTR) has officially begun. This approval gives Alnylam the early lead. Other competitors in the clinic include Ionis (NASDAQ:… read more...
Alnylam Pharmaceuticals (ALNY) Lumasarin Trial Data - Slideshow
via: SeekingAlpha at 2018-08-15 14:52:37:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Investors shun healthcare stocks in broad market selloff
via: SeekingAlpha at 2018-08-15 10:14:45:000
Healthcare stocks are taking it on the chin in today's broad selloff, some more than others. The SPDR S&P Biotech ETF ( XBI -2% ), for example, is down more than the major indexes. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Global Blood Therapeutics, Healthcare stoc… read more...
Your Daily Pharma Scoop: Redhill Receives NoA, Regeneron Gets CRL, Stemline NDA Under Review
via: SeekingAlpha at 2018-08-14 08:58:04:000
Stocks in News: RDHL, REGN RedHill Bio nabs U.S. patent covering RHB-104 and RHB-204 Discussion : RedHill Biopharma ( RDHL ) received a Notice of Allowance for its new formulation covering RHB-104 in Crohn's disease and RHB-204 in pulmonary nontuberculous mycobacteria infections. The … read more...
Alnylam Pharmaceutical's (ALNY) Conference Call to Discuss FDA Approval of ONPATTRO (Patisiran) - Slideshow
via: SeekingAlpha at 2018-08-13 13:39:48:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Premarket Losers as of 9:05 am (8/13/2018)
via: SeekingAlpha at 2018-08-13 09:16:29:000
DY -21% on cutting quarterly and full-year guidance. More news on: Dycom Industries Inc., Bright Scholar Education, RYB Education, Stocks on the move, , Read more … read more...
3 Things In Biotech, August 13: Rare Disease Approvals And Other Forward Momentum
via: SeekingAlpha at 2018-08-13 08:00:00:000
Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Alnylam clears the finish in amyloidosis Company: Alnylam Pharmaceuticals ( ALNY ) Therapy: Patisiran Disease:… read more...
Alnylam Receives First Ever FDA Approval For RNAi Therapeutic Treating Rare Disease Making History
via: SeekingAlpha at 2018-08-13 02:14:28:000
Recently, Alnylam Pharmaceuticals ( ALNY ) announced that it had received FDA approval for its drug Patisiran . This is the first of many approvals, because the EMA is also reviewing the drug for treating the same disease hereditary ATTR ((hATTR)) amyloidosis. The company has a pipeline f… read more...
Alnylam Announces Alignment on Value-Based Agreements with Leading Health Insurers and Launches Comprehensive Patient Support Services for ONPATTRO(TM) (patisiran)
via: Business Wire at 2018-08-10 14:37:00:000
Structure of Value-Based Arrangements Agreed in Principle with Harvard Pilgrim Health Care and Other Major Health Insurers Alnylam Assist Program Designed to Facilitate Access to ONPATTRO and Provide Dedicated Patient Support Alnylam P… read more...
Alnylam Announces Alignment on Value-Based Agreements with Leading Health Insurers and Launches Comprehensive Patient Support Services for ONPATTRO(TM) (patisiran)
via: Business Wire at 2018-08-10 14:37:00:000
Structure of Value-Based Arrangements Agreed in Principle with Harvard Pilgrim Health Care and Other Major Health Insurers Alnylam Assist Program Designed to Facilitate Access to ONPATTRO and Provide Dedicated Patient Support Alnylam P… read more...
Alnylam Announces Alignment on Value-Based Agreements with Leading Health Insurers and Launches Comprehensive Patient Support Services for ONPATTRO(TM) (patisiran)
via: Business Wire at 2018-08-10 14:37:00:000
Structure of Value-Based Arrangements Agreed in Principle with Harvard Pilgrim Health Care and Other Major Health Insurers Alnylam Assist Program Designed to Facilitate Access to ONPATTRO and Provide Dedicated Patient Support Alnylam P… read more...
Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO(TM) (patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
via: Business Wire at 2018-08-10 14:28:00:000
First and Only FDA-approved Treatment Available in the United States for this Indication ONPATTRO Shown to Improve Polyneuropathy Relative to Placebo, with Reversal of Neuropathy Impairment Compared to Baseline in Majority of Patients I… read more...
Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO(TM) (patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
via: Business Wire at 2018-08-10 14:28:00:000
First and Only FDA-approved Treatment Available in the United States for this Indication ONPATTRO Shown to Improve Polyneuropathy Relative to Placebo, with Reversal of Neuropathy Impairment Compared to Baseline in Majority of Patients I… read more...
Alnylam Announces First-Ever FDA Approval of an RNAi Therapeutic, ONPATTRO(TM) (patisiran) for the Treatment of the Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis in Adults
via: Business Wire at 2018-08-10 14:28:00:000
First and Only FDA-approved Treatment Available in the United States for this Indication ONPATTRO Shown to Improve Polyneuropathy Relative to Placebo, with Reversal of Neuropathy Impairment Compared to Baseline in Majority of Patients I… read more...
Alnylam shares halted pending news
via: SeekingAlpha at 2018-08-10 12:27:54:000
Nasdaq has suspended trading in Alnylam Pharmaceuticals ( ALNY +3.5% ) pending the release of news, most likely related to an FDA nod for patisiran for hATTR. The agency's action date is Saturday (meaning today). More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., H… read more...
Alnylam shares halted pending news
via: SeekingAlpha at 2018-08-10 12:27:54:000
Nasdaq has suspended trading in Alnylam Pharmaceuticals ( ALNY +3.5% ) pending the release of news, most likely related to an FDA nod for patisiran for hATTR. The agency's action date is Saturday (meaning today). More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., H… read more...
Alnylam shares halted pending news
via: SeekingAlpha at 2018-08-10 12:27:54:000
Nasdaq has suspended trading in Alnylam Pharmaceuticals ( ALNY +3.5% ) pending the release of news, most likely related to an FDA nod for patisiran for hATTR. The agency's action date is Saturday (meaning today). More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., H… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-07 07:50:38:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-07 07:50:38:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-08-07 07:50:38:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Hold rating and $17 (22% upside) price target at Stifel. More news on: ACADIA Pharmaceuticals Inc., Alder Biopharmaceuticals Inc., Alkermes plc, Healthcare stocks news, Stocks on the move, , Read more … read more...
Alnylam About A Week Away From Its First Approval
via: SeekingAlpha at 2018-08-06 08:02:36:000
With an FDA PDUFA date about one week away for its lead drug patisiran (which Alnylam ( ALNY ) will market as Onpattro), the value in the companys second quarter earnings report was mostly in regard to its pipeline updates. Alynylam has ample cash to continue moving i… read more...
Your Daily Pharma Scoop: Insmed's AdCom, Opko Progresses, Roche PRIMEd
via: SeekingAlpha at 2018-08-06 01:39:48:000
Stocks in News: INSM, OPK Insmed up 7% premarket ahead of Ad Com review of inhalable amikacin for NTM lung disease Discussion : Insmed ( INSM ) released briefing documents before upcoming Ad Com on Aug 7. The Ad Com will review the companys marketing application for amikacin l… read more...
Key events next week for healthcare investors
via: SeekingAlpha at 2018-08-03 07:58:17:000
Noteworthy events during the week of August 5-11 for healthcare investors. More news on: Insmed, Inc., Pain Therapeutics, Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
Key events next week for healthcare investors
via: SeekingAlpha at 2018-08-03 07:58:17:000
Noteworthy events during the week of August 5-11 for healthcare investors. More news on: Insmed, Inc., Pain Therapeutics, Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
Key events next week for healthcare investors
via: SeekingAlpha at 2018-08-03 07:58:17:000
Noteworthy events during the week of August 5-11 for healthcare investors. More news on: Insmed, Inc., Pain Therapeutics, Paratek Pharmaceuticals, Inc., Healthcare stocks news, , Read more … read more...
Alnylam Announces that the United Kingdom's MHRA Grants Early Access to Patisiran
via: Business Wire at 2018-08-03 07:00:00:000
Positive Scientific Opinion Under Early Access to Medicines Scheme will Make Patisiran Treatment Available for UK hATTR Amyloidosis Patients Before Marketing Authorization Patisiran Indicated Within EAMS for the Treatment of Adults with hATTR Amyloidosis … read more...
Alnylam Announces that the United Kingdom's MHRA Grants Early Access to Patisiran
via: Business Wire at 2018-08-03 07:00:00:000
Positive Scientific Opinion Under Early Access to Medicines Scheme will Make Patisiran Treatment Available for UK hATTR Amyloidosis Patients Before Marketing Authorization Patisiran Indicated Within EAMS for the Treatment of Adults with hATTR Amyloidosis … read more...
Alnylam Announces that the United Kingdom's MHRA Grants Early Access to Patisiran
via: Business Wire at 2018-08-03 07:00:00:000
Positive Scientific Opinion Under Early Access to Medicines Scheme will Make Patisiran Treatment Available for UK hATTR Amyloidosis Patients Before Marketing Authorization Patisiran Indicated Within EAMS for the Treatment of Adults with hATTR Amyloidosis … read more...
Alnylam Pharmaceuticals (ALNY) Q2 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-08-02 19:16:17:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2018 Earnings Call August 02, 2018 8:30 am ET Executives Christine Regan Lindenboom - Alnylam Pharmaceuticals, Inc. John M. Maraganore - Alnylam Pharmaceuticals, Inc. Yvonne L. Greenstreet - Alnylam Pharmaceuticals, Inc. Manmeet Singh Son… read more...
Alnylam Pharmaceuticals, Inc. 2018 Q2 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-08-02 10:26:44:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2018 Q2 earnings Read more … read more...
Alnylam Pharmaceuticals Q2 revenues up 88%
via: SeekingAlpha at 2018-08-02 09:34:19:000
Alnylam Pharmaceuticals ( ALNY +3.2% ) Q2 results : Revenues: $29.9M (+88.1%). More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Earnings news and commentary, Read more … read more...
Alnylam Pharmaceuticals beats by $0.16, beats on revenue
via: SeekingAlpha at 2018-08-02 08:02:08:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q2 EPS of -$1.61 beats by $0.16 . More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more … read more...
Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity
via: Business Wire at 2018-08-02 08:00:00:000
Received Positive CHMP Opinion for ONPATTRO in Europe for the Treatment of hATTR Amyloidosis in Adult Patients with Stage 1 or Stage 2 Polyneuropathy and On Track for August 11 PDUFA Date in U.S. Achieved Robust Enrollment in ENVISION Phase 3 Study of… read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-08-01 17:30:46:000
AAON , AAWW , ABC , ACIW , ACOR , AET , AGIO , ALE , ALNY , AMAG , AMCX , APO , APRN , ARES , AROC , ARW , AVP , BCE , BDX , BLL , BSIG , CBM , CBRE , CBZ , CCOI , CDW , CEIX , CHD , CI , CJ , CLX , CNQ , CNSL , CNX , CNXM , COT , CRS , CTSH , DNOW , … read more...
Your Daily Pharma Scoop: Tonix Halted, Endo Begins Shipment, Insys FDA-Rejected
via: SeekingAlpha at 2018-07-30 15:55:08:000
Stocks in News: ENDP, TNXP Tonix Pharma PTSD study fails; shares halted Discussion : The Phase 3 study of Tonix Pharmas ( TNXP ) Tonmya (previously TNX-102) in military-related PTSD will be halted. The decision is taken because, at week 12, the primary endpoint of separation f… read more...
Your Daily Pharma Scoop: Tonix Halted, Endo Begins Shipment, Insys FDA-Rejected
via: SeekingAlpha at 2018-07-30 15:55:08:000
Stocks in News: ENDP, TNXP Tonix Pharma PTSD study fails; shares halted Discussion : The Phase 3 study of Tonix Pharmas ( TNXP ) Tonmya (previously TNX-102) in military-related PTSD will be halted. The decision is taken because, at week 12, the primary endpoint of separation f… read more...
3 Things In Biotech, July 30: Europe News Continues To Dominate
via: SeekingAlpha at 2018-07-30 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Janssen headlines myeloma therapy in Europe Company: Johnson & Johnson ( JNJ ) and G… read more...
3 Things In Biotech, July 30: Europe News Continues To Dominate
via: SeekingAlpha at 2018-07-30 08:00:00:000
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. Janssen headlines myeloma therapy in Europe Company: Johnson & Johnson ( JNJ ) and G… read more...
Alnylam to Webcast Conference Call Discussing Second Quarter 2018 Financial Results
via: Business Wire at 2018-07-27 09:27:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2018 on Thursday, August 2, 2018, before the U.S. financial markets open. Management will provide an update … read more...
Alnylam to Webcast Conference Call Discussing Second Quarter 2018 Financial Results
via: Business Wire at 2018-07-27 09:27:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2018 on Thursday, August 2, 2018, before the U.S. financial markets open. Management will provide an update … read more...
Alnylam to Webcast Conference Call Discussing Second Quarter 2018 Financial Results
via: Business Wire at 2018-07-27 09:27:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2018 on Thursday, August 2, 2018, before the U.S. financial markets open. Management will provide an update … read more...
Alnylam Receives Positive CHMP Opinion for ONPATTRO(TM) (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy
via: Business Wire at 2018-07-27 07:15:00:000
European Commission Decision Expected in September Recommended Summary of Product Characteristics (SmPC) Includes Data on Secondary and Exploratory Endpoints, Including Results on Cardiac Parameters Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY… read more...
Alnylam Receives Positive CHMP Opinion for ONPATTRO(TM) (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy
via: Business Wire at 2018-07-27 07:15:00:000
European Commission Decision Expected in September Recommended Summary of Product Characteristics (SmPC) Includes Data on Secondary and Exploratory Endpoints, Including Results on Cardiac Parameters Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY… read more...
Alnylam Receives Positive CHMP Opinion for ONPATTRO(TM) (patisiran) for the Treatment of Hereditary Transthyretin-Mediated Amyloidosis in Adults with Stage 1 or Stage 2 Polyneuropathy
via: Business Wire at 2018-07-27 07:15:00:000
European Commission Decision Expected in September Recommended Summary of Product Characteristics (SmPC) Includes Data on Secondary and Exploratory Endpoints, Including Results on Cardiac Parameters Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY… read more...
Alnylam Pharmaceuticals (ALNY) Updates On Givosiran, in Development for the Treatment of Acute Hepatic Porphyrias (RNAi Roundtable) - Slideshow
via: SeekingAlpha at 2018-07-24 13:42:52:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Alnylam Pharmaceuticals (ALNY) Updates On Givosiran, in Development for the Treatment of Acute Hepatic Porphyrias (RNAi Roundtable) - Slideshow
via: SeekingAlpha at 2018-07-24 13:42:52:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Alnylam Pharmaceuticals (ALNY) Updates On Givosiran, in Development for the Treatment of Acute Hepatic Porphyrias (RNAi Roundtable) - Slideshow
via: SeekingAlpha at 2018-07-24 13:42:52:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Alnylam Presents New Analyses of Clinical Results from APOLLO Phase 3 Study of Patisiran at 2018 Peripheral Nerve Society Annual Meeting
via: Business Wire at 2018-07-23 07:00:00:000
Patisiran-Treated Patients Showed Improvements in Overall Health Status Compared to Placebo Indirect Analysis Shows Patisirans Impact on Measures of Neuropathy and Quality of Life in APOLLO Study Relative to those Measured in Randomized Study of Tafam… read more...
Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun
via: SeekingAlpha at 2018-07-18 16:03:11:000
While enthusiasm may be necessary for great accomplishments elsewhere, on Wall Street it almost invariably leads to disaster. -Benjamin Graham, The Intelligent Investor It's no wonder The Street has witnessed a 200% run-up over the past year for Arbutus Biopharma ( ABUS ). The Canadi… read more...
Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun
via: SeekingAlpha at 2018-07-18 16:03:11:000
While enthusiasm may be necessary for great accomplishments elsewhere, on Wall Street it almost invariably leads to disaster. -Benjamin Graham, The Intelligent Investor It's no wonder The Street has witnessed a 200% run-up over the past year for Arbutus Biopharma ( ABUS ). The Canadi… read more...
Arbutus Biopharma: Long-Term Growth Prospect Flying Too Close To The Sun
via: SeekingAlpha at 2018-07-18 16:03:11:000
While enthusiasm may be necessary for great accomplishments elsewhere, on Wall Street it almost invariably leads to disaster. -Benjamin Graham, The Intelligent Investor It's no wonder The Street has witnessed a 200% run-up over the past year for Arbutus Biopharma ( ABUS ). The Canadi… read more...
Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine
via: Business Wire at 2018-07-04 17:10:00:000
In Patients with Hereditary ATTR Amyloidosis, Patisiran Treatment Improved Polyneuropathy and Quality of Life Relative to Placebo Majority of Patients Receiving Patisiran Experienced Improvement in Polyneuropathy and Quality of Life Relative to Baseline "… read more...
Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine
via: Business Wire at 2018-07-04 17:10:00:000
In Patients with Hereditary ATTR Amyloidosis, Patisiran Treatment Improved Polyneuropathy and Quality of Life Relative to Placebo Majority of Patients Receiving Patisiran Experienced Improvement in Polyneuropathy and Quality of Life Relative to Baseline "… read more...
Alnylam Announces Publication of APOLLO Phase 3 Clinical Study Results for Investigational RNAi Therapeutic Patisiran in The New England Journal of Medicine
via: Business Wire at 2018-07-04 17:10:00:000
In Patients with Hereditary ATTR Amyloidosis, Patisiran Treatment Improved Polyneuropathy and Quality of Life Relative to Placebo Majority of Patients Receiving Patisiran Experienced Improvement in Polyneuropathy and Quality of Life Relative to Baseline "… read more...
Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation
via: SeekingAlpha at 2018-06-29 02:52:13:000
A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...
Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation
via: SeekingAlpha at 2018-06-29 02:52:13:000
A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...
Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation
via: SeekingAlpha at 2018-06-29 02:52:13:000
A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...
Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation
via: SeekingAlpha at 2018-06-29 02:52:13:000
A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...
Specialty Report On RNA-Based Therapeutics: A Novel Approach To Stellar Medicinal Innovation
via: SeekingAlpha at 2018-06-29 02:52:13:000
A stock is not just a ticker symbol or an electronic blip; it is an ownership interest in an actual business, with an underlying value that does not depend on its share price. - Benjamin Graham Welcome to the Integrated BioSci Specialty Report on RNA-based therapeutic innovators. As a … read more...
Alnylam Pharmaceuticals (ALNY) Platform Advances In RNAi Therapeutics - Slideshow
via: SeekingAlpha at 2018-06-26 13:55:03:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Alnylam Pharmaceuticals (ALNY) Platform Advances In RNAi Therapeutics - Slideshow
via: SeekingAlpha at 2018-06-26 13:55:03:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Alnylam Pharmaceuticals (ALNY) Platform Advances In RNAi Therapeutics - Slideshow
via: SeekingAlpha at 2018-06-26 13:55:03:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Alnylam to Host Fifth Annual "RNAi Roundtable" Webcast Series
via: Business Wire at 2018-06-21 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 5 th annual series of RNAi Roundtable webcasts this summer. The 2018 series will offer a range of presentations from Alnylam scientists, clin… read more...
Alnylam to Host Fifth Annual "RNAi Roundtable" Webcast Series
via: Business Wire at 2018-06-21 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 5 th annual series of RNAi Roundtable webcasts this summer. The 2018 series will offer a range of presentations from Alnylam scientists, clin… read more...
Alnylam Expands Senior Leadership Team with Two Key Appointments
via: Business Wire at 2018-06-20 07:00:00:000
Company Appoints Senior Vice President, Head of Asia and Senior Vice President, Head of Medical Affairs Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointments of two accomplished biotech executives… read more...
Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology
via: Business Wire at 2018-06-15 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, will be presented at t… read more...
Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology
via: Business Wire at 2018-06-15 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, will be presented at t… read more...
Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology
via: Business Wire at 2018-06-15 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, will be presented at t… read more...
Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology
via: Business Wire at 2018-06-15 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, will be presented at t… read more...
Alnylam to Report New Clinical Results for Patisiran at the 4th Congress of the European Academy of Neurology
via: Business Wire at 2018-06-15 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that additional results from the APOLLO Phase 3 study of patisiran, an investigational RNAi therapeutic for the treatment of hereditary ATTR (hATTR) amyloidosis, will be presented at t… read more...
Biotech industry group criticized for party featuring topless dancers
via: SeekingAlpha at 2018-06-13 12:05:05:000
Certain biotechs are scrambling to distance themselves from the uproar over a party at the 2018 BIO International Convention in Boston last week. Remarkably tone-deaf to the MeToo movement, the party featured topless dancers with company logos painted on their bodies. More news on: Bayer… read more...
Biotech industry group criticized for party featuring topless dancers
via: SeekingAlpha at 2018-06-13 12:05:05:000
Certain biotechs are scrambling to distance themselves from the uproar over a party at the 2018 BIO International Convention in Boston last week. Remarkably tone-deaf to the MeToo movement, the party featured topless dancers with company logos painted on their bodies. More news on: Bayer… read more...
Nash players perk up on Galmed surge
via: SeekingAlpha at 2018-06-12 11:25:16:000
Money flow has perked up in certain NASH players after Galmed Pharmaceuticals ( GLMD +183.4% ) reported positive results on Aramchol this morning. More news on: Galmed Pharmaceuticals Ltd., CymaBay Therapeutics, Intercept Pharmaceuticals, Healthcare stocks news, Stocks on the move, R… read more...
Over 700 Alnylam Employees Volunteer at the Company's 4th Annual "Helping Hands" Community Service Day
via: Business Wire at 2018-06-12 08:00:00:000
Alnylam Supports 23 Local Organizations in theGreater Boston Area and Western Europe Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), the leading RNAi therapeutics company, today kicked off its fourth annual company-wide Helping Hands Communi… read more...
Alnylam Pharmaceuticals Continues To Develop Options Outside Of Amyloidosis
via: SeekingAlpha at 2018-06-12 07:48:32:000
With a $10 billion market cap, its hard to call Alnylam ( ALNY ) overlooked, but I do believe the shares of this maturing biotech are undervalued as the company approaches a window that should see multiple new product approvals through 2020. Most recently, Alnylam has offered up some… read more...
Your Daily Pharma Scoop: Zealand Dips, Eloxx Surges, Venetoclax Approved
via: SeekingAlpha at 2018-06-11 08:00:00:000
Analysis Focus: ZEAL Zealand Pharma ( ZEAL ) is a small Danish company that specializes in gastroenteric and metabolic diseases. The company has late-stage clinical programs with glepaglutide and three dasiglucagon product candidates. They also have a late-stage program in Phase 3 developm… read more...
3 Things In Biotech, June 9: AbbVie Rules The CLL Roost
via: SeekingAlpha at 2018-06-10 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! What else do you get from me with a subscription? Welcome to another edition of "3 Things In Biotech You Should Learn Today," … read more...
Eidos Therapeutics Readies $100 Million U.S. IPO
via: SeekingAlpha at 2018-06-08 12:01:02:000
Quick Take Eidos Therapeutics ( EIDX ) intends to sell shares of its common stock for gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement. The firm is a subsidiary of BridgeBio Pharma with the mission to improve and prolong the lives of patients s… read more...
Eidos Therapeutics Readies $100 Million U.S. IPO
via: SeekingAlpha at 2018-06-08 12:01:02:000
Quick Take Eidos Therapeutics ( EIDX ) intends to sell shares of its common stock for gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement. The firm is a subsidiary of BridgeBio Pharma with the mission to improve and prolong the lives of patients s… read more...
Alnylam's lumasiran shows positive effect in Phase 1/2 PH1 study
via: SeekingAlpha at 2018-06-08 07:20:19:000
Updated results from a Phase 1/2 clinical trial assessing Alnylam Pharmaceuticals' (NASDAQ: ALNY ) lumasiran in patients with primary hyperoxaluria type 1 (PH1) continued to show a treatment effect. The data were presented at OxalEurope in Naples, Italy. More news on: Alnylam Pharmaceut… read more...
Alnylam's lumasiran shows positive effect in Phase 1/2 PH1 study
via: SeekingAlpha at 2018-06-08 07:20:19:000
Updated results from a Phase 1/2 clinical trial assessing Alnylam Pharmaceuticals' (NASDAQ: ALNY ) lumasiran in patients with primary hyperoxaluria type 1 (PH1) continued to show a treatment effect. The data were presented at OxalEurope in Naples, Italy. More news on: Alnylam Pharmaceut… read more...
Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
via: Business Wire at 2018-06-08 07:00:00:000
Patients Receiving Investigational Lumasiran Experienced Substantial and Sustained Reductions in Urinary Oxalate, Confirming Potential for RNAi-Mediated Inhibition of Glycolate Oxidase as a Robust Therapeutic Approach for PH1 Lumasiran Generally Well Tolerate… read more...
Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1 (PH1)
via: Business Wire at 2018-06-08 07:00:00:000
Patients Receiving Investigational Lumasiran Experienced Substantial and Sustained Reductions in Urinary Oxalate, Confirming Potential for RNAi-Mediated Inhibition of Glycolate Oxidase as a Robust Therapeutic Approach for PH1 Lumasiran Generally Well Tolerate… read more...
Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells
via: SeekingAlpha at 2018-06-08 03:06:02:000
The best way to measure your investing success is not by whether you're beating the market but by whether you've put in place a financial plan and a behavioral discipline that are likely to get you where you want to go. - Benjamin Graham We have presented many stellar therapeutic… read more...
Akcea And Ionis: What The Latest Regulatory Catalyst For Inotersen Foretells
via: SeekingAlpha at 2018-06-08 03:06:02:000
The best way to measure your investing success is not by whether you're beating the market but by whether you've put in place a financial plan and a behavioral discipline that are likely to get you where you want to go. - Benjamin Graham We have presented many stellar therapeutic… read more...
Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up
via: SeekingAlpha at 2018-06-06 01:36:03:000
Analysis Focus:IOVA Iovance Biotherapeutics (IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2… read more...
Your Daily Pharma Scoop: Iovance Zooms Ahead, Palatin Surges And Deciphera Moves Up
via: SeekingAlpha at 2018-06-06 01:36:03:000
Analysis Focus:IOVA Iovance Biotherapeutics (IOVA) is a small biopharma with about $1.3bn in market cap. This is our well-known Lion Bio which shot to some prominence last year and also changed its name to Iovance. Their lead product candidate is LN-144, an adoptive cell therapy in Phase 2… read more...
Alnylam receives ODD for ALN-TTRsc02 in U.S. for the treatment of transthyretin-mediated amyloidosis
via: SeekingAlpha at 2018-06-04 08:07:54:000
The FDA grants Orphan Drug Designation to Alnylam Pharmaceuticals' (NASDAQ: ALNY ), ALN-TTRsc02, an investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Alnylam receives ODD for ALN-TTRsc02 in U.S. for the treatment of transthyretin-mediated amyloidosis
via: SeekingAlpha at 2018-06-04 08:07:54:000
The FDA grants Orphan Drug Designation to Alnylam Pharmaceuticals' (NASDAQ: ALNY ), ALN-TTRsc02, an investigational RNAi therapeutic for the treatment of transthyretin-mediated amyloidosis. More news on: Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Read more … read more...
Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
via: Business Wire at 2018-06-04 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALN-TTRsc02, an investigational RNAi therapeutic for the treatment of transthyretin-mediated… read more...
Alnylam Receives Orphan Drug Designation from the United States Food & Drug Administration for ALN-TTRsc02, a Subcutaneously Delivered Investigational RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
via: Business Wire at 2018-06-04 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to ALN-TTRsc02, an investigational RNAi therapeutic for the treatment of transthyretin-mediated… read more...
Thoughts On Joel Greenblatt At Google
via: SeekingAlpha at 2018-06-04 05:58:56:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) When An Investment Method Stops Working Each week for the past year, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an " investing … read more...
Thoughts On Joel Greenblatt At Google
via: SeekingAlpha at 2018-06-04 05:58:56:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) When An Investment Method Stops Working Each week for the past year, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an " investing … read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Bulletproof Investing Performance Update: Week 27
via: SeekingAlpha at 2018-06-01 02:42:50:000
Safety First: Sprint Racer McKenna Haase and her helmet (via Racing News ) Bulletproof Investing: Week 27 Performance Each week since the beginning of June, I have presented at least two hedged portfolios created by Portfolio Armor to my Bulletproof Investing subscribers. This is an… read more...
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
via: Business Wire at 2018-05-29 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Bernstein 34 th Annual Strategic Decisions Conference on Friday, June 1, 2018 at 9:00 am ET at the Grand … read more...
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
via: Business Wire at 2018-05-29 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Bernstein 34 th Annual Strategic Decisions Conference on Friday, June 1, 2018 at 9:00 am ET at the Grand … read more...
Alnylam to Webcast Presentations at Upcoming June Investor Conferences
via: Business Wire at 2018-05-29 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: Bernstein 34 th Annual Strategic Decisions Conference on Friday, June 1, 2018 at 9:00 am ET at the Grand … read more...
Eidos Therapeutics files for initial public offering
via: SeekingAlpha at 2018-05-25 17:13:24:000
Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...
Eidos Therapeutics files for initial public offering
via: SeekingAlpha at 2018-05-25 17:13:24:000
Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...
Eidos Therapeutics files for initial public offering
via: SeekingAlpha at 2018-05-25 17:13:24:000
Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...
Eidos Therapeutics files for initial public offering
via: SeekingAlpha at 2018-05-25 17:13:24:000
Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...
Eidos Therapeutics files for initial public offering
via: SeekingAlpha at 2018-05-25 17:13:24:000
Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...
Eidos Therapeutics files for initial public offering
via: SeekingAlpha at 2018-05-25 17:13:24:000
Eidos Therapeutics has filed for an initial public offering with an initial registration for $115M. More news on: Pfizer Inc., Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Healthcare stocks news, IPOs, Read more … read more...
3 Things In Biotech, May 24: Immunotherapy Makes Yet Another Foray
via: SeekingAlpha at 2018-05-25 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...
3 Things In Biotech, May 24: Immunotherapy Makes Yet Another Foray
via: SeekingAlpha at 2018-05-25 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...
3 Things In Biotech, May 24: Immunotherapy Makes Yet Another Foray
via: SeekingAlpha at 2018-05-25 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...
3 Things In Biotech, May 24: Immunotherapy Makes Yet Another Foray
via: SeekingAlpha at 2018-05-25 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...
3 Things In Biotech, May 24: Immunotherapy Makes Yet Another Foray
via: SeekingAlpha at 2018-05-25 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...
3 Things In Biotech, May 24: Immunotherapy Makes Yet Another Foray
via: SeekingAlpha at 2018-05-25 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...
Institutional Top Ideas Series: Perceptive Advisors
via: SeekingAlpha at 2018-05-24 01:54:56:000
In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...
Institutional Top Ideas Series: Perceptive Advisors
via: SeekingAlpha at 2018-05-24 01:54:56:000
In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...
Institutional Top Ideas Series: Perceptive Advisors
via: SeekingAlpha at 2018-05-24 01:54:56:000
In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...
Institutional Top Ideas Series: Perceptive Advisors
via: SeekingAlpha at 2018-05-24 01:54:56:000
In the last entry of this series, we took a look at top ideas from Opaleye Management, one of the best performing funds we've come across so far thats been growing its AUM at an impressive rate. Going forward, I hope to continue to delve into the portfolios of successful hedge funds … read more...
Alnylam Appoints Colleen Reitan to the Board of Directors
via: Business Wire at 2018-05-15 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylams Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of… read more...
Alnylam Appoints Colleen Reitan to the Board of Directors
via: Business Wire at 2018-05-15 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylams Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of… read more...
Alnylam Appoints Colleen Reitan to the Board of Directors
via: Business Wire at 2018-05-15 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylams Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of… read more...
Alnylam Appoints Colleen Reitan to the Board of Directors
via: Business Wire at 2018-05-15 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylams Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of… read more...
Alnylam Appoints Colleen Reitan to the Board of Directors
via: Business Wire at 2018-05-15 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylams Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of… read more...
Alnylam Appoints Colleen Reitan to the Board of Directors
via: Business Wire at 2018-05-15 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the appointment of a veteran healthcare leader, Colleen Reitan, to Alnylams Board of Directors, effective June 1, 2018. Ms. Reitan was the prior President of Plan Operations of… read more...
Biotech Analysis Central Pharma News: Takeda's Acquisition Win, Ionis And Akcea Tumble, Alnylam's Advance In CNS
via: SeekingAlpha at 2018-05-09 01:40:03:000
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Takeda Acquires Shire For $62 Billion News: It was announced recently that Takeda ( TKPYY ) would pay $62 billion in total to acquire rare disea… read more...
Biotech Analysis Central Pharma News: Takeda's Acquisition Win, Ionis And Akcea Tumble, Alnylam's Advance In CNS
via: SeekingAlpha at 2018-05-09 01:40:03:000
Welcome to Biotech Analysis Central Daily News, a daily news report and analysis about what has happened lately in the biotech industry. Takeda Acquires Shire For $62 Billion News: It was announced recently that Takeda ( TKPYY ) would pay $62 billion in total to acquire rare disea… read more...
Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics
via: Business Wire at 2018-05-08 07:00:00:000
Novel siRNA Conjugates Achieve Robust, Durable, and Broadly Distributed Silencing of CNS Gene Transcripts Following a Single Intrathecal Injection Company Expects First CNS-Targeted Development Candidate in 2018, First IND in Late 2019/Early 2020, and Capacit… read more...
Alnylam Reports Preclinical Data Demonstrating Central Nervous System (CNS) Delivery of RNAi Therapeutics
via: Business Wire at 2018-05-08 07:00:00:000
Novel siRNA Conjugates Achieve Robust, Durable, and Broadly Distributed Silencing of CNS Gene Transcripts Following a Single Intrathecal Injection Company Expects First CNS-Targeted Development Candidate in 2018, First IND in Late 2019/Early 2020, and Capacit… read more...
Alnylam Gets A Shortcut For Lumasiran... This News Is Highly Welcome
via: SeekingAlpha at 2018-05-08 00:53:33:000
It was recently announced that Alnylam Pharmaceuticals ( ALNY ) was able to obtain a quicker path to approval for lumasiran. This will put the biotech ahead of schedule with approval of another one of its drugs in the pipeline possibly by 2020. That's because it is expecting a decision from … read more...
Alnylam Gets A Shortcut For Lumasiran... This News Is Highly Welcome
via: SeekingAlpha at 2018-05-08 00:53:33:000
It was recently announced that Alnylam Pharmaceuticals ( ALNY ) was able to obtain a quicker path to approval for lumasiran. This will put the biotech ahead of schedule with approval of another one of its drugs in the pipeline possibly by 2020. That's because it is expecting a decision from … read more...
Despite Recurrent Market Jitters, Alnylam Is Closing In On Multiple Drug Approvals
via: SeekingAlpha at 2018-05-07 08:00:12:000
Holding shares in Alnylam Pharmaceuticals ( ALNY ) isnt for the weak-hearted, as seen recently in reaction to a competitors unexpectedly strong clinical data. While Alnylam has long been volatile, and remains risky given the nature of the diseases it targets and its reliance … read more...
Despite Recurrent Market Jitters, Alnylam Is Closing In On Multiple Drug Approvals
via: SeekingAlpha at 2018-05-07 08:00:12:000
Holding shares in Alnylam Pharmaceuticals ( ALNY ) isnt for the weak-hearted, as seen recently in reaction to a competitors unexpectedly strong clinical data. While Alnylam has long been volatile, and remains risky given the nature of the diseases it targets and its reliance … read more...
Your Daily Pharma Scoop: Alnylam Update, Malinckrodt's Adcom Failure, Anika's Drug Recall
via: SeekingAlpha at 2018-05-07 08:00:00:000
Analysis focus: ALNY Alnylam (ALNY), a leading RNAi therapeutics company, reported earnings last week. It beat on EPS, which at -$1.22 beat by $0.25. However, its revenue , despite rising 15% y/y, stood at $21.9mn, $8.25mn short of consensus. So, the company must have managed to cut costs… read more...
Your Daily Pharma Scoop: Alnylam Update, Malinckrodt's Adcom Failure, Anika's Drug Recall
via: SeekingAlpha at 2018-05-07 08:00:00:000
Analysis focus: ALNY Alnylam (ALNY), a leading RNAi therapeutics company, reported earnings last week. It beat on EPS, which at -$1.22 beat by $0.25. However, its revenue , despite rising 15% y/y, stood at $21.9mn, $8.25mn short of consensus. So, the company must have managed to cut costs… read more...
3 Things In Biotech, May 4: Merck's New Combo, Alnylam Jump Starts, Ocata Gone Forever?
via: SeekingAlpha at 2018-05-05 08:54:11:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...
3 Things In Biotech, May 4: Merck's New Combo, Alnylam Jump Starts, Ocata Gone Forever?
via: SeekingAlpha at 2018-05-05 08:54:11:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Try for free today and see what we're talking about! Here is some more information if you're curious . Welcome to another edition of "3 Things In Biotech," a daily digest dedicated… read more...
FDA extends action date for Akcea's inotersen to October 6; shares down 6% premarket
via: SeekingAlpha at 2018-05-04 09:25:07:000
Akcea Therapeutics (NASDAQ: AKCA ) announces that the FDA has established a new action date of October 6 for the review of its marketing application seeking approval for inotersen, branded as TEGSEDI, for the treatment of hereditary transthyretin amyloidosis (hATTR). The agency extended it… read more...
FDA extends action date for Akcea's inotersen to October 6; shares down 6% premarket
via: SeekingAlpha at 2018-05-04 09:25:07:000
Akcea Therapeutics (NASDAQ: AKCA ) announces that the FDA has established a new action date of October 6 for the review of its marketing application seeking approval for inotersen, branded as TEGSEDI, for the treatment of hereditary transthyretin amyloidosis (hATTR). The agency extended it… read more...
Alnylam Pharmaceuticals (ALNY) Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-04 00:55:05:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2018 Earnings Call May 03, 2018 4:30 pm ET Executives Christine Regan Lindenboom - Alnylam Pharmaceuticals, Inc. John M. Maraganore - Alnylam Pharmaceuticals, Inc. Akshay K. Vaishnaw - Alnylam Pharmaceuticals, Inc. Manmeet Singh Soni - Al… read more...
Alnylam Pharmaceuticals (ALNY) Q1 2018 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-05-04 00:55:05:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2018 Earnings Call May 03, 2018 4:30 pm ET Executives Christine Regan Lindenboom - Alnylam Pharmaceuticals, Inc. John M. Maraganore - Alnylam Pharmaceuticals, Inc. Akshay K. Vaishnaw - Alnylam Pharmaceuticals, Inc. Manmeet Singh Soni - Al… read more...
Alnylam Pharmaceuticals, Inc. 2018 Q1 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-05-03 22:49:20:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2018 Q1 earnings Read more … read more...
Alnylam Pharmaceuticals (ALNY) Presents At BIO CEO & Investor Conference - Slideshow
via: SeekingAlpha at 2018-02-13 13:56:52:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with this Read more … read more...
Biotech Forum Daily Digest For February 12th
via: SeekingAlpha at 2018-02-12 10:14:39:000
T here are some days we can claim and there are other days that claim us . Kamand Kojouri Investors got treated like 'rented mules' this week as the markets suffered their worst weekly loss in some two years. Four of the five trading sessions featured over 1,000 point sw… read more...
Biotech Forum Daily Digest For February 12th
via: SeekingAlpha at 2018-02-12 10:14:39:000
T here are some days we can claim and there are other days that claim us . Kamand Kojouri Investors got treated like 'rented mules' this week as the markets suffered their worst weekly loss in some two years. Four of the five trading sessions featured over 1,000 point sw… read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-02-09 12:34:12:000
Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-02-09 12:34:12:000
Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-02-09 12:34:12:000
Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-02-09 12:34:12:000
Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...
Key events next week - healthcare
via: SeekingAlpha at 2018-02-09 12:34:12:000
Noteworthy events for the week of Feb. 11 - 17 for healthcare investors: More news on: Humanigen, Inc., Can-Fite Biopharma Ltd, Invitae, Healthcare stocks news, Read more … read more...
Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results
via: SeekingAlpha at 2018-02-09 08:00:00:000
Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...
Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results
via: SeekingAlpha at 2018-02-09 08:00:00:000
Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...
Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results
via: SeekingAlpha at 2018-02-09 08:00:00:000
Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...
Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results
via: SeekingAlpha at 2018-02-09 08:00:00:000
Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...
Your Daily Pharma Scoop: Adamas' Gocovri Key Value Driver, BioMarin Data, Regeneron Q4 Results
via: SeekingAlpha at 2018-02-09 08:00:00:000
Analysis of top Seeking Alpha coverage: Adamas Pharmaceuticals Today we will focus on Adamas Pharmaceuticals ( ADMS ). On Thursday, the company reported data from the EASE LID 2 study. Adamas got an approval for Gocovri last year, the first treatment for levodopa induced dyskinesia i… read more...
Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-08 20:12:04:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2017 Earnings Conference Call February 08, 2018 4:30 PM ET Executives Christine Lindenboom Vice President-Investor Relations and Corporate Communications John Maraganore Chief Executive Officer Akshay Vaishnaw Exe… read more...
Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-08 20:12:04:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2017 Earnings Conference Call February 08, 2018 4:30 PM ET Executives Christine Lindenboom Vice President-Investor Relations and Corporate Communications John Maraganore Chief Executive Officer Akshay Vaishnaw Exe… read more...
Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-08 20:12:04:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2017 Earnings Conference Call February 08, 2018 4:30 PM ET Executives Christine Lindenboom Vice President-Investor Relations and Corporate Communications John Maraganore Chief Executive Officer Akshay Vaishnaw Exe… read more...
Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-08 20:12:04:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2017 Earnings Conference Call February 08, 2018 4:30 PM ET Executives Christine Lindenboom Vice President-Investor Relations and Corporate Communications John Maraganore Chief Executive Officer Akshay Vaishnaw Exe… read more...
Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2017 Results - Earnings Call Transcript
via: SeekingAlpha at 2018-02-08 20:12:04:000
Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2017 Earnings Conference Call February 08, 2018 4:30 PM ET Executives Christine Lindenboom Vice President-Investor Relations and Corporate Communications John Maraganore Chief Executive Officer Akshay Vaishnaw Exe… read more...
Alnylam Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-02-08 13:30:18:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...
Alnylam Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-02-08 13:30:18:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...
Alnylam Pharmaceuticals, Inc. 2017 Q4 - Results - Earnings Call Slides
via: SeekingAlpha at 2018-02-08 13:30:18:000
The following slide deck was published by Alnylam Pharmaceuticals, Inc. in conjunction with their 2017 Q4 earnings Read more … read more...
Alnylam Pharmaceuticals beats by $0.19, beats on revenue
via: SeekingAlpha at 2018-02-08 08:01:32:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q4 EPS of -$1.20 beats by $0.19 . Revenue of $37.9M (+117.2% Y/Y) beats by $16.1M . Press Release More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...
Alnylam Pharmaceuticals beats by $0.19, beats on revenue
via: SeekingAlpha at 2018-02-08 08:01:32:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q4 EPS of -$1.20 beats by $0.19 . Revenue of $37.9M (+117.2% Y/Y) beats by $16.1M . Press Release More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...
Alnylam Pharmaceuticals beats by $0.19, beats on revenue
via: SeekingAlpha at 2018-02-08 08:01:32:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q4 EPS of -$1.20 beats by $0.19 . Revenue of $37.9M (+117.2% Y/Y) beats by $16.1M . Press Release More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...
Alnylam Pharmaceuticals beats by $0.19, beats on revenue
via: SeekingAlpha at 2018-02-08 08:01:32:000
Alnylam Pharmaceuticals (NASDAQ: ALNY ): Q4 EPS of -$1.20 beats by $0.19 . Revenue of $37.9M (+117.2% Y/Y) beats by $16.1M . Press Release More news on: Alnylam Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, read more...
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity
via: Business Wire at 2018-02-08 08:00:00:000
Reported Final Results from APOLLO Phase 3 Study and Completed Filings of New Drug Application (NDA) and Marketing Authorisation Application (MAA) for Patisiran, with an Expected Commercial Launch in U.S. and Europe in Mid- and Late 2018, Respectively Advance… read more...
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity
via: Business Wire at 2018-02-08 08:00:00:000
Reported Final Results from APOLLO Phase 3 Study and Completed Filings of New Drug Application (NDA) and Marketing Authorisation Application (MAA) for Patisiran, with an Expected Commercial Launch in U.S. and Europe in Mid- and Late 2018, Respectively Advance… read more...
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity
via: Business Wire at 2018-02-08 08:00:00:000
Reported Final Results from APOLLO Phase 3 Study and Completed Filings of New Drug Application (NDA) and Marketing Authorisation Application (MAA) for Patisiran, with an Expected Commercial Launch in U.S. and Europe in Mid- and Late 2018, Respectively Advance… read more...
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Highlights Recent Period Activity
via: Business Wire at 2018-02-08 08:00:00:000
Reported Final Results from APOLLO Phase 3 Study and Completed Filings of New Drug Application (NDA) and Marketing Authorisation Application (MAA) for Patisiran, with an Expected Commercial Launch in U.S. and Europe in Mid- and Late 2018, Respectively Advance… read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-02-07 17:30:01:000
ABB , ALNY , ALXN , BCE , BR , BWA , CAH , CBG , CBM , COR , COTY , CVS , EPC , FAF , GLPI , GOOS , GPI , GRA , GRUB , GT , GWR , HBI , K , KKR , LCII , MANU , MAS , MD , MDSO , MLCO , MMS , MMYT , MPW , NJR , NLSN , NS , NYT , ODFL , PAG , PENN , PM… read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-02-07 17:30:01:000
ABB , ALNY , ALXN , BCE , BR , BWA , CAH , CBG , CBM , COR , COTY , CVS , EPC , FAF , GLPI , GOOS , GPI , GRA , GRUB , GT , GWR , HBI , K , KKR , LCII , MANU , MAS , MD , MDSO , MLCO , MMS , MMYT , MPW , NJR , NLSN , NS , NYT , ODFL , PAG , PENN , PM… read more...
Notable earnings before Thursday's open
via: SeekingAlpha at 2018-02-07 17:30:01:000
ABB , ALNY , ALXN , BCE , BR , BWA , CAH , CBG , CBM , COR , COTY , CVS , EPC , FAF , GLPI , GOOS , GPI , GRA , GRUB , GT , GWR , HBI , K , KKR , LCII , MANU , MAS , MD , MDSO , MLCO , MMS , MMYT , MPW , NJR , NLSN , NS , NYT , ODFL , PAG , PENN , PM… read more...
Alnylam to Webcast Presentations at Upcoming February Investor Conferences
via: Business Wire at 2018-02-05 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present company overviews at the following conferences: 20 th Annual BIO CEO & Investor Conference on Monday, February 12, 2018 at 10:45 am ET at the Marriot… read more...
3 Things In Biotech You Should Learn Today: February 3, 2018
via: SeekingAlpha at 2018-02-04 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...
3 Things In Biotech You Should Learn Today: February 3, 2018
via: SeekingAlpha at 2018-02-04 08:00:00:000
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec… read more...
Ionis: Good Value With Non-Binary Upside
via: SeekingAlpha at 2018-02-02 11:59:15:000
Antisense Technology Ionis ( IONS ) is considered to be one of the leaders in discovering and developing RNA-targeted therapeutics. Ionis has created a broadly applicable drug discovery antisense technology platform to develop a large, diverse, and advanced pipeline of potentially first-in… read more...
Ionis: Good Value With Non-Binary Upside
via: SeekingAlpha at 2018-02-02 11:59:15:000
Antisense Technology Ionis ( IONS ) is considered to be one of the leaders in discovering and developing RNA-targeted therapeutics. Ionis has created a broadly applicable drug discovery antisense technology platform to develop a large, diverse, and advanced pipeline of potentially first-in… read more...
Ionis: Good Value With Non-Binary Upside
via: SeekingAlpha at 2018-02-02 11:59:15:000
Antisense Technology Ionis ( IONS ) is considered to be one of the leaders in discovering and developing RNA-targeted therapeutics. Ionis has created a broadly applicable drug discovery antisense technology platform to develop a large, diverse, and advanced pipeline of potentially first-in… read more...
Ionis: Good Value With Non-Binary Upside
via: SeekingAlpha at 2018-02-02 11:59:15:000
Antisense Technology Ionis ( IONS ) is considered to be one of the leaders in discovering and developing RNA-targeted therapeutics. Ionis has created a broadly applicable drug discovery antisense technology platform to develop a large, diverse, and advanced pipeline of potentially first-in… read more...
U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018
via: SeekingAlpha at 2018-02-02 06:43:19:000
Market and sector outlook: No change in the bullish near-term outlook on S&P 500 index ( SPY ) from yesterday. The market Buy signal using VIX indicator continues. We expect Nasdaq Biotechnology Index ( IBB ) to also recover and make new highs. Up on >5x volume (excluding pen… read more...
U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018
via: SeekingAlpha at 2018-02-02 06:43:19:000
Market and sector outlook: No change in the bullish near-term outlook on S&P 500 index ( SPY ) from yesterday. The market Buy signal using VIX indicator continues. We expect Nasdaq Biotechnology Index ( IBB ) to also recover and make new highs. Up on >5x volume (excluding pen… read more...
U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018
via: SeekingAlpha at 2018-02-02 06:43:19:000
Market and sector outlook: No change in the bullish near-term outlook on S&P 500 index ( SPY ) from yesterday. The market Buy signal using VIX indicator continues. We expect Nasdaq Biotechnology Index ( IBB ) to also recover and make new highs. Up on >5x volume (excluding pen… read more...
U.S. Biotech/Pharma Sector Daily Observations Letter: February 1, 2018
via: SeekingAlpha at 2018-02-02 06:43:19:000
Market and sector outlook: No change in the bullish near-term outlook on S&P 500 index ( SPY ) from yesterday. The market Buy signal using VIX indicator continues. We expect Nasdaq Biotechnology Index ( IBB ) to also recover and make new highs. Up on >5x volume (excluding pen… read more...
FDA accepts Alnylam's patisiran NDA for hATTR amyloidosis, action date August 11
via: SeekingAlpha at 2018-02-01 16:20:25:000
The FDA accepts for review Alnylam Pharmaceuticals' (NASDAQ: ALNY ) marketing application seeking approval for patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis. The agency's action date is August 11 under Priority Review status. More news on: Alnylam Pharmaceuticals, In… read more...
FDA accepts Alnylam's patisiran NDA for hATTR amyloidosis, action date August 11
via: SeekingAlpha at 2018-02-01 16:20:25:000
The FDA accepts for review Alnylam Pharmaceuticals' (NASDAQ: ALNY ) marketing application seeking approval for patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis. The agency's action date is August 11 under Priority Review status. More news on: Alnylam Pharmaceuticals, In… read more...
FDA accepts Alnylam's patisiran NDA for hATTR amyloidosis, action date August 11
via: SeekingAlpha at 2018-02-01 16:20:25:000
The FDA accepts for review Alnylam Pharmaceuticals' (NASDAQ: ALNY ) marketing application seeking approval for patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis. The agency's action date is August 11 under Priority Review status. More news on: Alnylam Pharmaceuticals, In… read more...
Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
via: Business Wire at 2018-02-01 16:00:00:000
PDUFA date set for August 11, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for patisiran, an inve… read more...
Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
via: Business Wire at 2018-02-01 16:00:00:000
PDUFA date set for August 11, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for patisiran, an inve… read more...
Alnylam Announces FDA Acceptance of New Drug Application (NDA) and Priority Review Status for Patisiran, an Investigational RNAi Therapeutic for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
via: Business Wire at 2018-02-01 16:00:00:000
PDUFA date set for August 11, 2018 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing its New Drug Application (NDA) for patisiran, an inve… read more...
Miragen Therapeutics May Provide Long Term Alpha Within The RNA Space
via: SeekingAlpha at 2018-02-01 10:49:29:000
Written by Dan Cohen and Scott Matusow Recently, we had a conference call with a Miragen Therapeutics ( MGEN ) , and left the call impressed with what we heard. CEO Bill Marshall was frank and to-the-point, and was able to answer all of our questions regarding the science and busine… read more...
Miragen Therapeutics May Provide Long Term Alpha Within The RNA Space
via: SeekingAlpha at 2018-02-01 10:49:29:000
Written by Dan Cohen and Scott Matusow Recently, we had a conference call with a Miragen Therapeutics ( MGEN ) , and left the call impressed with what we heard. CEO Bill Marshall was frank and to-the-point, and was able to answer all of our questions regarding the science and busine… read more...
Miragen Therapeutics May Provide Long Term Alpha Within The RNA Space
via: SeekingAlpha at 2018-02-01 10:49:29:000
Written by Dan Cohen and Scott Matusow Recently, we had a conference call with a Miragen Therapeutics ( MGEN ) , and left the call impressed with what we heard. CEO Bill Marshall was frank and to-the-point, and was able to answer all of our questions regarding the science and busine… read more...
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results
via: Business Wire at 2018-02-01 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2017 on Thursday, February 8, 2018, before the U.S. financial markets open. Management will pro… read more...
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results
via: Business Wire at 2018-02-01 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2017 on Thursday, February 8, 2018, before the U.S. financial markets open. Management will pro… read more...
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2017 Financial Results
via: Business Wire at 2018-02-01 07:00:00:000
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the fourth quarter and year ending December 31, 2017 on Thursday, February 8, 2018, before the U.S. financial markets open. Management will pro… read more...
Sanofi Scoops Up Ablynx: Start Of A Buyout Spree?
via: SeekingAlpha at 2018-01-31 03:09:26:000
Ablynx ( ABLX ) has become the latest takeover success story, with drug giant Sanofi ( SNY ) offering $4.8 billion in cash for the Belgian biotech. Sanofis bid far outstrips that of Novo Nordisk ( NVO ), which had offered $3.1 billion earlier this month. Sanofi has been adding to… read more...
Sanofi Scoops Up Ablynx: Start Of A Buyout Spree?
via: SeekingAlpha at 2018-01-31 03:09:26:000
Ablynx ( ABLX ) has become the latest takeover success story, with drug giant Sanofi ( SNY ) offering $4.8 billion in cash for the Belgian biotech. Sanofis bid far outstrips that of Novo Nordisk ( NVO ), which had offered $3.1 billion earlier this month. Sanofi has been adding to… read more...
Sanofi Scoops Up Ablynx: Start Of A Buyout Spree?
via: SeekingAlpha at 2018-01-31 03:09:26:000
Ablynx ( ABLX ) has become the latest takeover success story, with drug giant Sanofi ( SNY ) offering $4.8 billion in cash for the Belgian biotech. Sanofis bid far outstrips that of Novo Nordisk ( NVO ), which had offered $3.1 billion earlier this month. Sanofi has been adding to… read more...
Your Daily Pharma Scoop: Sanofi To Acquire Ablynx, PTC Therapeutics Announces Data, Lutathera Approved
via: SeekingAlpha at 2018-01-30 08:00:00:000
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss Sanofis ( SNY ) takeover offer for Belgian biotech Ablynx ( ABLYF ). Ablyx had earlier this month rejected a hostile takeover offer from Novo Nordisk ( NVO ), noting that euro 30.50 per share offer undervalued … read more...
Your Daily Pharma Scoop: Sanofi To Acquire Ablynx, PTC Therapeutics Announces Data, Lutathera Approved
via: SeekingAlpha at 2018-01-30 08:00:00:000
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss Sanofis ( SNY ) takeover offer for Belgian biotech Ablynx ( ABLYF ). Ablyx had earlier this month rejected a hostile takeover offer from Novo Nordisk ( NVO ), noting that euro 30.50 per share offer undervalued … read more...
Your Daily Pharma Scoop: Sanofi To Acquire Ablynx, PTC Therapeutics Announces Data, Lutathera Approved
via: SeekingAlpha at 2018-01-30 08:00:00:000
Analysis of top Seeking Alpha coverage: Ablynx Today we will discuss Sanofis ( SNY ) takeover offer for Belgian biotech Ablynx ( ABLYF ). Ablyx had earlier this month rejected a hostile takeover offer from Novo Nordisk ( NVO ), noting that euro 30.50 per share offer undervalued … read more...
Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results
via: SeekingAlpha at 2018-01-26 13:01:52:000
Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...
Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results
via: SeekingAlpha at 2018-01-26 13:01:52:000
Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...
Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results
via: SeekingAlpha at 2018-01-26 13:01:52:000
Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...
Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results
via: SeekingAlpha at 2018-01-26 13:01:52:000
Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...
Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results
via: SeekingAlpha at 2018-01-26 13:01:52:000
Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...
Your Daily Pharma Scoop: A Look At Advaxis, AstraZeneca's Positive Results, AbbVie Reports Q4 Results
via: SeekingAlpha at 2018-01-26 13:01:52:000
Analysis of top Seeking Alpha coverage: Advaxis Today we will discuss Advaxis ( ADXS ), which announced on Thursday that its lead candidate axalimogene filolisbac showed positive effect in early-stage anal cancer. The news pushed ADXS shares nearly 5% higher in trading on Thursday. The … read more...
European marketing application for Alnylam's patisiran accepted for review, action date late June
via: SeekingAlpha at 2018-01-25 16:16:08:000
The European Medicines Agency (EMA) accepts for review Alnylam Pharmaceuticals' (NASDAQ: ALNY ) marketing application seeking approval for patisiran for the treatment of hereditary ATTR amyloidosis. Under previously granted accelerated assessment, the agency's action date is about June 24…. read more...
European marketing application for Alnylam's patisiran accepted for review, action date late June
via: SeekingAlpha at 2018-01-25 16:16:08:000
The European Medicines Agency (EMA) accepts for review Alnylam Pharmaceuticals' (NASDAQ: ALNY ) marketing application seeking approval for patisiran for the treatment of hereditary ATTR amyloidosis. Under previously granted accelerated assessment, the agency's action date is about June 24…. read more...
Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
via: Business Wire at 2018-01-25 16:00:00:000
EMA Will Evaluate MAA Under Accelerated Assessment Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) and initiated… read more...
Alnylam Announces EMA Acceptance of Marketing Authorisation Application (MAA) for Patisiran for the Treatment of Hereditary ATTR (hATTR) Amyloidosis
via: Business Wire at 2018-01-25 16:00:00:000
EMA Will Evaluate MAA Under Accelerated Assessment Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the European Medicines Agency (EMA) has accepted the Marketing Authorisation Application (MAA) and initiated… read more...
Sanofi: What To Think About The Bioverativ Acquisition?
via: SeekingAlpha at 2018-01-24 15:23:03:000
On January 22nd, Sanofi ( SNY ) has announced the acquisition of Bioverativ ( BIVV ) for $ 11.6B in cash ( 9.5B). The deal price represents a 64% premium to the previous day's closing price. A quick overview of Bioverativ Bioverativ (spun off from Biogen ( BIIB )) is a US biotech c… read more...
Ionis Pharmaceuticals Is Poised To Disrupt Biotech
via: SeekingAlpha at 2018-01-23 21:11:37:000
I have written this article with the layperson in mind, but I will try to stay true to the underlying science. Targeting the "undruggable" The general mantra of traditional biopharmaceuticals is to develop chemical-based drugs that affect a particular protein, altering a disease process… read more...
The Medicines Co's inclisiran an Orphan Drug in U.S. for HoFH; shares up 3%
via: SeekingAlpha at 2018-01-23 12:22:07:000
The FDA designates The Medicines Company's ( MDCO +2.5% ) inclisiran an Orphan Drug for the treatment of homozygous familial hypercholesterolemia (HoFH), an inherited disorder characterized by extremely high levels of "bad" cholesterol in the blood. More news on: The Medicines Compan… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-01-19 07:23:23:000
Intellipharmaceutics (NASDAQ: IPCI ) initiated with Buy rating and $2.50 (213% upside) price target by H.C. Wainwright. More news on: IntelliPharmaCeutics International Inc, PLx Pharma, Vanda Pharmaceuticals Inc., Healthcare stocks news, Read more … read more...
Stocks To Watch: Guidance Updates All Around
via: SeekingAlpha at 2018-01-13 10:15:28:000
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. Earnings season heats up this week with more big names likely to follow in the path… read more...
When The Bulls Growl And The Bears Moo - Stock Market Outlook 2018
via: SeekingAlpha at 2018-01-10 09:15:19:000
Market Pulse The year 2017 will be remembered as the year when the Bulls Growled and the Bears Mooed. A year when stock market volatility for the first time ever subsided to a level below that of bonds. A year when the market refused to relent to the historical valuation templates and hand… read more...
Your Daily Pharma Scoop: Aradigm Sees Sell-Off Ahead Of Ad Com, Editas Provides Update, Axsome Suffers Setback
via: SeekingAlpha at 2018-01-10 01:14:42:000
Analysis of top Seeking Alpha coverage: Aradigm Today we will discuss the much-anticipated FDA briefing documents for Aradaigms ( ARDM ) Linhaliq. The documents were made available today ahead of the Ad Com meeting on Thursday, January 11 th . Following the release of the docu… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|